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1 Abstract
Airway inflammation is a key feature of bronchial asthma. In asthma management, 
according to international guidelines, the gold standard is anti-inflammatory treatment. 
Currently, only conventional procedures (i.e., symptoms, use of rescue medication, PEF-
variability, and lung function tests) were used to both diagnose and evaluate the results of 
treatment with anti-inflammatory drugs. New methods for evaluation of degree of airway 
inflammation are required. 
Nitric oxide (NO) is a gas which is produced in the airways of healthy subjects and 
especially produced in asthmatic airways. Measurement of NO from the airways is 
possible, and NO can be measured from exhaled air. Fractional exhaled NO (FENO) is 
increased in asthma, and the highest concentrations are measured in asthmatic patients 
not treated with inhaled corticosteroids (ICS). Steroid-treated patients with asthma had 
levels of FENO similar to those of healthy controls. Atopic asthmatics had higher levels of 
FENO than did nonatopic asthmatics, indicating that level of atopy affected FENO level. 
Associations between FENO and bronchial hyperresponsiveness (BHR) occur in asthma. 
The present study demonstrated that measurement of FENO had good reproducibility, and 
the FENO variability was reasonable both short- and long-term in both healthy subjects 
and patients with respiratory symptoms or asthma. We demonstrated the upper normal 
limit for healthy subjects, which was 12 ppb calculated from two different healthy study 
populations. We showed that patients with respiratory symptoms who did not fulfil the 
diagnostic criteria of asthma had FENO values significantly higher than in healthy subjects, 
but significantly lower than in asthma patients. 
These findings suggest that BHR to histamine is a sensitive indicator of the effect of ICS 
and a valuable tool for adjustment of corticosteroid treatment in mild asthma. The findings 
further suggest that intermittent treatment periods of a few weeks’ duration are insufficient 
to provide long-term control of BHR in patients with mild persistent asthma. Moreover, 
during the treatment with ICS changes in BHR and changes in FENO were associated. 
FENO level was associated with BHR measured by a direct (histamine challenge) or 
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indirect method (exercise challenge) in steroid-naïve symptomatic, non-smoking 
asthmatics. Although these associations could be found only in atopics, FENO level in 
nonatopic asthma was also increased. 
It can thus be concluded that assessment of airway inflammation by measuring FENO can 
be useful for clinical purposes. The methodology of FENO measurements is now 
validated. Especially in those patients with respiratory symptoms who did not fulfil the 
diagnostic criteria of asthma, FENO measurement can aid in treatment decisions. Serial 
measurement of FENO during treatment with ICS can be a complementary or an 
alternative method for evaluation in patients with asthma. 
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2 Abbreviations
AMP Adenoside monophosphate 
ATS American Thoracic Society 
BHR Bronchial hyperresponsiveness 
BMI Body mass index 
CI Confidence interval 
CoV Coefficient of variation 
COPD Chronic obstructive pulmonary disease 
DD Doubling dose 
ECP Eosinophilic cationic protein 
EIB Exercise-induced bronchoconstriction 
ERS European Respiratory Society 
FENO Exhaled nitric oxide 
FP Fluticasone propionate 
FEV1 Forced expiratory volume in one second 
FVC Forced vital capacity 
HDM House dust mite 
HIB Histamine-induced bronchoconstriction 
ICS Inhaled corticosteroids 
IgE Immunoglobulin E 
IL Interleukin 
iNOS Inducible nitric oxide syntethase 
MEF50 Maximal expiratory flow at 50% of FVC 
NO Nitric oxide 
PC20 Provocative concentration of histamine causing a 20% fall in FEV1 
PD15FEV1 Provocative dose of histamine causing a 15% fall in FEV1 
PEF Peak expiratory flow 
ROC Receiver operating characteristic 
SPT Skin prick test 
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4 Introduction
The word "asthma" is derived from the Greek, meaning "to pant heavily" or "gasp for 
breath". The term originally did not define a disease as we understand it today, but was 
employed to connote respiratory symptoms of a host of pulmonary and cardiac conditions. 
Over time, the meaning contracted and by the beginning of the last century, most 
authorities thought asthma to be a unique illness characterized by "spasmodic afflictions of 
the bronchial tubes" (Osler 1901). In 1922, Huber and colleagues examined the 
microscopic features of 15 reported deaths and added 6 cases of their own. Their work 
described the classic features of patients dying from asthma, including mucous impaction 
in the bronchi; thickening of the airway walls; hypertrophy of the smooth muscle; edema of 
the submucosa; and eosinophilic, lymphoid, and neutrophilic infiltration (Huber et al. 1922). 
They also undertook the first attempt at quantifying the extent of abnormalities present and 
correlating them with the type and severity of the patient's asthma. Dunnill (1960) added 
mucosal denudation and thickening of the basement membranes of the airways to the list. 
These features have been repeatedly demonstrated in the inflammatory reactions in the
airways of patients who die of asthma (Dunnill 1969). 
Asthma is a chronic inflammatory disorder which tends to increase, affecting about 6% 
people in Finland (Kotaniemi et al. 2001) and over 100 million people worldwide (Global 
Initiative for Asthma, NHLBI, 1995). Asthma produces an economic burden on health care, 
and the cost of medical treatment of asthma was 280 million marks in Finland in 1994. 
Clinical evidence that airway inflammation plays the major role in the development of 
asthma was presented more than 20 years ago (Laitinen et al. 1985, Bousquet et al. 
1990). Airway inflammation is central to the development of asthma and underlies the 
clinical features of asthma, which are bronchial hyperresponsiveness and variable airway 
obstruction (Djucanovic et al. 1990). Knowledge of inflammatory mechanisms in asthma 
has accumulated recently, and new treatment modes for asthma have been developed in 
the past decade.
In 1993 it was first reported that levels of exhaled nitric oxide (FENO) were increased in 
bronchial asthma compared to those of healthy controls (Alving et al. 1993), and was 
demonstrated that patients with asthma treated with oral or inhaled steroids had levels of 
exhaled nitric oxide similar to those of healthy controls (Kharitonov et al. 1994). Exhaled 
nitric oxide might therefore be a new marker of airway inflammation (Barnes and 
Kharitonov 1996). 
In the present series of investigations, the aim was to examine with two methodological 
studies the FENO levels in healthy subjects and the long-term variation and also short-
term variability of FENO in healthy subjects and patients with suspected asthma. 
Secondly, the aim was to evaluate the short-term effects of inhaled fluticasone (FP) on 
FENO and bronchial hyperesponsiveness (BHR) in mild asthma. Furthermore, we 
examined the association between exhaled nitric oxide, exercise-induced 
bronchoconstriction (EIB), and bronchial hyperesponsiveness in patients with suspected 
asthma. In addition, we studied levels of FENO in patients with nonatopic asthma 
compared with those of healthy subjects and low- and high-sensitised atopic asthmatics.
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5 Review of the literature 
5.1 Nitric oxide (NO) 
5.1.1 What is nitric oxide? 
NO is a gas under atmospheric conditions but soluble within cells and tissues. Its solubility 
and diffusion properties resemble closely those of oxygen. NO is chemically reactive, but 
for a radical it is relatively stable and it does not react with itself, and it has a physiological 
half-life of seconds to minutes depending on its concentration and immediate chemical 
environment (Wink et al. 1996). 
5.1.2 Production of NO 
NO is synthesised universally from L-arginine and molecular oxygen by an enzymatic 
process that utilises electrons donated by NADPH. The NO synthase (NOS) enzymes 
convert L-arginine to NO and L-citrulline via intermediate N-hydroxy-L-arginine.  
Figure 1.Synthesis of NO and NO-relates products. Modified from Kharitonov and Barnes 
(2001).
There are three types of NOS. Two of these are constitutively expressed, while the other is 
expressed only in activated cells. One constitutive form was originally characterised in 
neurons and was therefore known as neuronal NOS (nNOS), while the other, originally 
characterised in endothelial cells, was known as endothelial NOS (eNOS). These two NOS 
isoforms have been renamed NOS-1 and NOS-3 (Nathan et al. 1994). The third type of 
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NOS is not expressed in resting cells, but is synthesised upon cell activation. This 
inducible form of NOS is known either iNOS or NOS-2 (Stuehr et al. 1997). 
The constitutive forms of NOS (nNOS and eNOS) are activated in response to a calcium 
signal generated for example by the arrival of an action potential at a nerve ending, or 
activation of endothelial cell receptors by acetylcholine. Enzyme activation occurs rapidly 
and transiently, according to the kinetics of the calcium signal (Moncada et al. 1991). 
INOS, on the other hand, is not activated by a calcium signal but is continuously active 
once expressed. Its expression is induced by several agents including cytokines such as 
interferon-?, interleukin-1 (IL-1), and tumor necrosis factor- ? (TNF-?) (Nathan et al. 1994). 
At high concentrations, as produced by the inducible form of NOS and under aerobic 
conditions, NO is rapidly oxidised to reactive nitrogen oxide species (RNOS) with the 
generic formula NOx. Under gaseous conditions, the RNOS formed are nitrogen dioxide 
(NO2), dinitrogen trioxide (N203), and dinitrogen tetraoxide (N204), but in aqueous solution, 
and in a biological system, N203 is the major oxidative product (Wink et al. 1996). Under 
conditions of combined nitrosative and oxidative stress, when both NO and the superoxide 
anion (O2-) are formed at high concentrations, these two radicals interact to generate the 
highly reactive oxidant peroxynitrite anion (ONOO-) (Figure 1).  Peroxynitrite is thought to 
mediate many of the most severe toxic effects of NO (Wink et al. 1996). 
5.1.3 NO in asthmatic inflammation 
NO is generated at high levels during human inflammatory reactions such as asthma 
(Kharitonov et al. 1994) and, as in the immune response, the principal NOS isotype 
involved is iNOS (Figure 2) (Robbins et al. 1994). Higher iNOS expression has been 
reported in bronchial biopsies from patients with asthma than in healthy subjects (Hamid et 
al. 1993; Belvisi et al. 1995). Furthermore, iNOS expression can be reduced by 
corticosteroids (Saleh et al. 1998; Redington et al. 2001). Epithelial cells have been shown 
to express iNOS the most, but macrophages, eosinophils, and smooth muscle cells 
express iNOS as well (Saleh et al. 1998; Reddington et al. 2001). Only iNOS expression 
was associated with FENO in respiratory epithelial cells obtained from children, suggesting 
that FENO variability is largely determined by epithelial iNOS expression with little 
contribution from other isoforms (Lane et al. 2004). Certainly the role of NO in 
inflammation considered to be uncertain. NO has toxic, regulatory, apoptotic and anti-
apoptotic effects on different cell types at different stages of the inflammatory process. 
In IgE-mediated inflammatory disease such as asthma, the activation of mast cells by 
antigens is the first event. Mast cells release mediators which cause classic inflammation 
but also cytokines, such as TNF-?, that may promote the later phases of inflammation by 
recruiting other inflammatory cell types. NO inhibits mast cell activation and mediates the 
inhibitory effects of IFN-? on mast cells in mixed cell populations. NO has been found to 
inhibit secretion of IL-2 and IFN-? in Th1-lymphocytes. NO may also regulate the balance 
between Th1-and Th2-lymphocytes and may favour the Th2 response, which activates 
secretion of IL-4 and IL-5, causing more IgE production and eosinophil recruitment 
(Barnes and Liew 1995).  Studies with knock-out mice and iNOS-inhibitors are so 
conflicting that clinical implications for human asthmatics are modest. 
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Figure 2. Sources of NO in exhaled air in asthma. Modified from Kharitonov and Barnes, 
2001.
5.1.4 Measurement of exhaled nitric oxide 
Gustaffsson and colleagues (1991) reported that exhaled NO is endogenously produced in 
rabbits, guinea-pigs, and humans. This pioneering study demonstrated that NO can be in 
the exhaled air of all three species, with no NO in inhaled air. They also demonstrated that 
when NOS inhibitors were used for test animals, the levels of NO were decreased and 
further administration of l-arginine raised NO levels back to normal. 
In 1993 Alving and colleagues reported that exhaled NO is increased in asthma in 
humans. The fundamental studies, which were published simultaneously in the Lancet in 
1994, finally demonstrated that measurement of exhaled NO can be used in diagnosis and 
treatment of asthma (Kharitonov et al. 1994; Persson et al. 1994). These studies 
confirmed that patients with steroid-naïve asthma had an increased level of exhaled NO 
compared to that of healthy controls. Moreover, patients with steroid-treated asthma had
levels of exhaled NO similar to the levels of healthy subjects. Furthermore, smoking 
patients with asthma had lower levels of exhaled NO than did patients with steroid-naïve 
asthma. These findings showed that a non-invasive method to assess airways 
inflammation is possible, and for that reason methodological and clinical aspects of 
exhaled nitric oxide will be discussed. 
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Figure 3.   Diagram of one configuration for the breathing circuit employed in the restricted 
breath technique (Modified from ATS 1999). 
5.1.4.1 Chemiluminescence method 
Exhaled NO is measured by the chemiluminescence method (Figure 3). It is based on the 
reaction between NO and the ozone (O3), which is generated from the ozone generator in 
the analyzer. NO and ozone form nitrogen dioxide (NO2), part of which is the excited form 
NO2*. When the excited form of NO2 resumes its stable form, light is emitted and can be 
quantified by a photomultiplier. The amount of light emitted is proportional to the amount of 
NO in gas collected from samples (Figure 4).
5.1.4.2 Exhalation procedure 
Earlier studies used tidal breathing or slow vital capacity manoeuvres. The method with 
tidal breathing is easy to perform, but the level of exhaled NO varies in the course of the 
breathing cycle; therefore, no constant level of FENO can be achieved. Breathholding was 
used to maximise the concentrations of FENO, which allowed nasal NO to mix with 
exhaled NO. Wearing a nose-clip during measurement keeps the soft palate from 
inadequately closing; nasal NO can contaminate the levels of FENO. The first studies used 
the peak-FENO measurement which starts with high peak-NO concentration (probably 
caused during breathholding) and after that, levels of FENO in the end-expiratory phase (= 
plateau) representing the endogenous level of FENO in the lower airways. Recently 
introduced standardised methods will be measured with a standardised expiratory flow 
rate without breathholding and without a nose-clip (Kharitonov et al. 1997; ATS 1999 and 
ATS/ERS Recommendation 2005). 
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Figure 4 Schematic presentation of an ozone-chemiluminescence NO analyser 
5.1.4.3 Exhalation flow rate 
Flow-dependency has the greatest effect on FENO. The level of FENO decreases with 
increasing flow rates and vice versa. This is partly explained by the fact that increased 
ventilation reduces the concentration of FENO in the bronchial tree. Moreover, the 
repeatability of FENO is dependent on expiratory flow, and low variation in expiratory flow 
reduces variation in FENO. With a controlled exhalation flow rate, the variability of FENO 
is low.
With a standardised expiratory flow rate there is no possibility of contamination of FENO 
from the nasal sinuses at slow exhalation flow rates. Therefore, during production of low 
positive mouth pressure with a resistor, the soft palate will be closed to prevent 
contamination from the nasal cavities (Figure 5). Devices to achieve mouth pressures from 
5 to 20 cmH2O are recommended during FENO measurement see section 5.1.6. 
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Figure 5. Schematic presentation of FENO procedure (exhalation against resistance 
produce positive mouth pressure which closes the soft palate). Modified from Kharitonov 
and Barnes (1998). 
One application of FENO measurement is a two-compartment model of the lungs 
(Tsoukias and Georges 1998). Several clinically important findings were published with 
this method (Lehtimäki 2003). 
5.1.4.4 Peak exhaled nitric oxide 
During the first years of FENO measurement, the procedure was not standardised. After 
breathholding with a noseclip, subjects exhaled with different flows. This procedure 
ensured that the maximum amount of NO is released from the airways, and this peak 
amount of NO was measured. Current knowledge confirms that previous methods of NO 
measurement were inadequate. 
5.1.5 Factors affecting FENO level 
Several factors affect the level of FENO in healthy subjects as well as in patients (Table 1).
5.1.5.1 Diet
NO can be produced in the oral cavity by a non-enzymatic reduction from nitrite. The acid 
environment and bacteria in the oral cavity cause the formation of nitrate to nitrite and 
further to NO.  Zetterquist and colleagues (1999) have shown that ingestion of a meal rich 
with nitrate prior to FENO measurement increases the level of FENO. When the mouth is 
rinsed with a basic solution or anti-bacterial solution, this increase in FENO can be partly 
eliminated. Caffeine and alcohol consumption have been shown to reduce the level of 
FENO (Yates et al. 1996; Persson et al. 1992), but a recent study by Taylor et al. (2004) 
showed that caffeine had no effect on FENO. 
5.1.5.2 Other factors 
Repeated spirometry reduces the level of FENO (Silkoff et al. 1999; Deykin et al. 2000), 
and the short-acting beta-agonist after spirometry leads to an increased level of FENO 
(Yates et al. 1997). Physical exercise and sputum induction can reduce FENO level 
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(Phillips et al. 1996: Piacentini et al. 2000), if these procedures have been done before 
FENO measurement. Therefore, measurement of FENO should be done before lung 
function measurements (including measurement of bronchial hyperresponsiveness), and 
before any exercise test or sputum induction. 
5.1.5.3 Smoking
Smoking reduces the level of FENO (Kharitonov et al. 1995; Robbins et al. 1996). High 
levels of NO occur in cigarette smoke and may affect endogenous NO production in 
smokers by downregulation of cNOS activity. Increased metabolic consumption of NO in 
smokers has also been postulated, which is a reaction of NO with superoxide, producing 
peroxynitrite. In any case, the level of FENO increases gradually during the 4 weeks after 
cessation of smoking (Högman et al. 2002). 
Table 1 Factors affecting exhaled nitric oxide
(FENO) measurements in healthy subjects
• Upper respiratory tract 
infection
• Intake of l-arginine, ACE-
inhibitors, papaverin, 
sodium nitroprusside
• Nitrite / Nitrate-enriched 
food
• Air pollution (ozone, NO)
• Occupational risks 
(chlorine dioxide, ozone, 
formaldehyde)
• NOS inhibitors
• Smoking (acute and 
passive)
• Alcohol ingestion
• Caffeine
• Mid-point ot the 
menstrual cycle
• Repeated spirometry
• Physical exercise
• Sputum induction
• 100% inhaled oxygen
• Moderate altitude
Increased NO Decreased NO
5.1.6 International guidelines of FENO measurement 
During the development of measurement of FENO, several factors affecting FENO have 
been found. The most important is flow-dependency (Silkoff et al. 1997), and an effect 
from exhalation manoeuvres and positive mouth pressure has also been detected. 
Because the validity of FENO must be evaluated, international guidelines have therefore 
been published to standardise measument technique, the European Respiratory Society 
(ERS) published the first guidelines of FENO measurement in 1997 (Kharitonov et al. 
1997). In these guidelines, several steps in FENO measurement have been standardised 
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to minimise the variation in FENO and bring closer the conflicting findings of different 
researchers. ERS guidelines suggest an exhalation flow range of between 0.167 mL/s and 
250 mL/s (10–15 L/min). 
Guidelines from the American Thoracic Society (ATS 1999) recommend that the 
exhalation flow should be a constant 0.050 mL/s. Variation in plateau should be less than 
or equal to 10% or 1 ppb and less than or equal to 5% of variation between the three 
measurements. Mouth rinsing with a basic solution is recommended in ATS guidelines. 
Recent guidelines from ATS/ERS combine the best elements from previous guidelines 
(ATS 2005). 
A new hand-held device (NIOX MINO) for the measurement of FENO has been developed 
with a different assay for measuring FENO levels in exhaled air. A good correlation 
appeared between the NIOX MINO and standard FENO analysers (Khalili et al. 2007).
5.2 Bronchial hyperresponsiveness (BHR) 
5.2.1 What is BHR? 
BHR is currently defined as an increase in sensitivity to a wide variety of airway-narrowing 
stimuli. Most patients with asthma and chronic obstructive pulmonary disease (COPD) 
exhibit such an enhanced sensitivity. In asthma, in particular, this hypersensitivity is 
accompanied by excessive degrees of airway narrowing. Bronchial hyperresponsiveness 
is a composite functional disorder which requires treatment of each of its components 
(Sterk and Bel 1989). BHR is a fundamental abnormality in asthma, representing both 
structural and inflammatory changes in the airways due to the disease process. 
5.2.2 BHR and genetics 
The association between BHR and genetics is a matter of conflict. The 5q region has been 
studied with respect to phenotypes such as asthma and BHR (Postma et al. 1995) in 
differing populations. Recent meta-analysis used a rank-based genome-scan meta-
analysis (GSMA) to combine linkage data for asthma and related traits: BHR, allergen-
positive skin prick test (SPT), and IgE in nine Caucasian asthma populations. They found 
significant evidence that susceptibility loci could be identified for quantitative traits 
including BHR 2p12-q22.1, 6p22.3-p21.1 and 11q24.1-qter; allergen SPT 3p22.1-q22.1 
and 17p12-q24.3; and total IgE 5q11.2-q14.3 and 6pter-p22.3. Analysis of the asthma 
phenotype did not identify any region showing genome-wide significance. This study 
represents the first linkage meta-analysis to determine the relative contribution of 
chromosomal regions to risk for developing asthma and atopy. Several significant results 
were obtained for quantitative traits but not for asthma, confirming the greater numbers of 
phenotypes and greater genetic heterogeneity in asthma. These analyses support the 
contribution of regions that contain previously identified asthma susceptibility genes and 
provide the first evidence for susceptibility loci on 5q11.2-q14.3 and 11q24.1-qter (Denham 
et al. 2008). 
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5.2.3 Methods for evaluation of BHR 
Both direct and indirect challenge tests can be used for evaluation of asthma, as in the 
standard definition: ”The inflammation also causes an associated increase in airway 
responsiveness to a variety of stimuli”.  
5.2.4 Direct challenges 
There are several methods to evaluate BHR in direct challenges. Acetylcholine, 
metacholine, carbachol, histamine, prostaglandin D2, and leukotriene C-E4 have been 
used for both clinical and research purposes. The most often used direct challenges 
(histamine, methacholine provocation tests) can caused a marked bronchoconstriction in 
asthmatics but not in healthy subjects. Both tests are pharmacological stimuli that cause 
bronchoconstiction by directly activating contraction of bronchial smooth muscle cells after 
binding to cholinergic receptors or histamine receptors. The physiological basis of this 
increased contractility remains fundamentally unresolved. Increased BHR to histamine is 
more prominent in chronic asthma when compared to newly detected asthma (Sovijärvi et 
al 1993). Recently, use of BHR as an additional guide to long-term treatment in clinical 
control of asthma has shown that more effective control of asthma can be achieved (Sont 
et al 1999). 
5.2.5 Indirect challenges 
During indirect challenges, stimuli cause airflow limitation by an action on cells other than 
the effector cells; these cells then interact a second time with the effector cells. Cells that 
act as an intermediary between the indirect stimuli and effector cells are inflammatory cells 
(such as mast cells) and neuronal cells. Different challenges have been used in both 
clinical and experimental studies: adenoside, tachykinins (substance A and neurokinin A), 
bradykinin, metabisulphite, mannitol, propranolol, cold air ventilation, exercise, hypertonic 
saline, and isocapnic hyperventilation (van Schoor et al. 2000).  
Exercise testing is a basic measurement for study of children and young adults with 
suspicion of asthma. Exercise-induced asthma (EIB) is a phenomenon existing only in 
asthma. There is no evidence of EIB after exercise in healthy subjects; on the contrary 
healthy subjects and patients with COPD exhibit bronchodilation. The severity of EIB is 
clearly relevant to the severity of asthma in children and young adults. EIB is a short-term 
response to exercise, and spontaneous recovery is usually complete within an hour; no 
evidence for a late asthmatic reaction after exercise was found in 404 young men with 
asthma (Karjalainen 1991). In sum, evidence is sufficient to suggest that the release of 
constrictor mediators: histamine, prostaglandins, and leukotrienes is an important 
contributor to the bronchoconstriction induced by exercise and hyperventilation. The 
relative contribution of these mediators has not been determined, and it is likely that 
among individuals with EIB, the relative actions of these mediators vary. Presumably, 
airway cooling and drying during exercise constitutes the stimuli for mediator release. 
There may even be a direct role for exercise as a stimulus (Gilbert et al. 1993) for mediator 
release, although this has been little studied. In addition, bronchodilating mechanisms may 
play a more significant role in modifying the action of these constricting mediators than 
previously thought. Agents such as mast cell-produced heparin and PGE2, atrial natriuretic 
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peptide, kinins, substance P, vasoactive intestinal peptide, plus other vasoactive agents 
may also play a modifying role in EIB, although much more investigation is required before 
specific roles can be assigned.
Figure 6. Schematic of potential sites for mechanisms of exercised-induced 
bronchospasm.  Modified from Gotshall (2002). 
Whereas exercise may provide multiple stimuli for EIB, hyperpnoea is the dominant 
stimulus inducing EIB (Figure 6). Cooling and drying, and possibly rewarming, affect 
airways, resulting in local multiple inflammatory mediator release of which prostaglandins 
and especially leukotrienes and histamine are important. Airway narrowing occurs post- 
exercise as mediators, possibly along with rewarming, cause bronchoconstriction, vascular 
engorgement and leakage, and increased mucus production (Figure 6). The airways 
narrow progressively post-exercise, peaking from 3 to 10 minutes typically. The 
obstruction dissipates over time, resolving in 30 to 60 minutes. This is followed by a 
refractory period of up to 3 hours that is dependent on prostaglandins that protect the 
airways from subsequent periods of exercise (Virant 1992). 
Osmotic challenges with mannitol (Brannan et al. 1998) have been used as alternative 
surrogate tests to identify EIB in individuals with clinically recognized asthma. Relative to 
exercise and eucapnic voluntary hyperventilation, the osmotic challenges require less 
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complex and expensive equipment. The mannitol challenge, in particular, has the potential 
to be used in field, clinic, and laboratory environments to identify EIB in elite athletes. The 
response to mannitol fell within the normal range in asymptomatic subjects with BHR to 
methacholine and may be a more specific test for diagnosing asthma (Porsbjerg et al. 
2007). BHR to mannitol also seems to be a more sensitive marker than BHR to 
metacholine in asthma patients not under treatment with steroids (Koskela et al. 2003), 
and in their study, BHR to mannitol reflected the degree of airway inflammation more 
closely than did BHR to methacholine. Furthermore, mannitol is more sensitive than cold 
air in demonstrating BHR in patients with mild or atypical asthma, and if specific cut-off 
values are used, sensitivity values of mannitol and histamine challenges were comparable 
(Koskela et al. 2003).
Mannitol challenge is both a sensitive and a valid test to demonstrate the effects of ICS in 
asthma. Histamine challenge is equally sensitive for this purpose, but its validity may be 
lower. Cold air challenge seems to be a valid test to demonstrate the effects of ICS, but its 
sensitivity may be lower than that of mannitol and histamine challenges (Koskela et al. 
2003). Moreover, mannitol is a convenient challenge which is easy to administer and well-
tolerated by children. It is a highly reproducible test of BHR in children with moderate to 
severe persistent asthma who are on inhaled corticosteroids for 7 days under laboratory 
conditions (Barber et al. 2003) 
A study by Berkman and colleagues (2005) compared exercise, metacholine, and AMP as 
diagnostic tools for asthma and found that the ROC curves were comparable; furthermore, 
they concluded that measurement of FENO can be used as a safe, simple, and rapid test 
for the diagnosis of asthma and is as good as bronchial provocation tests. 
5.3 Asthma
5.3.1 Definition of asthma 
The International Consensus Report on the Diagnosis and Treatment of Asthma (1992) 
defined asthma as follows: “Asthma is a chronic inflammatory disorder of the airways in 
which many cells play a role, in particular mast cells, eosinophils and T-lymphocytes. In 
susceptible individuals, this inflammation causes recurrent episodes of wheezing, 
breathlessness, chest tightness and cough particularly at night and / or in the early 
morning. These symptoms are usually associated with widespread but variable airflow 
limitation that is at least partly reversible either spontaneous or with treatment. The 
inflammation also causes an associated increase in airway responsiveness to a variety of 
stimuli”. Of course, asthma has more heterogeneity than in the definition of the Consensus 
Report. No single feature or group of features is common to all asthmatics (Howell 1995).
For research purposes, asthma is defined by the criteria of the Global Initiative for Asthma, 
NHLBI (2007): “An increased BHR to metacholine or histamine (specific cutoff values 
depend on method used), a PEF variability across 24 hours (amplitude percent mean) of 
20 percent or more, and an increase in FEV1 of 15 percent or more from baseline with an 
inhaled short-acting beta2-agonist. In children and young adults the exercise test with a 15 
percent fall in PEF or FEV1 from baseline has found to be diagnostic”. For clinical 
purposes, asthma is defined by its components or a combination of these: obstruction 
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measured with FEV1 or PEF, bronchial hyperresponsiveness, increased level of 
eosinophils or ECP in induced sputum, atopy measured by total or specific serum IgE or a 
skin prick test. 
5.3.2 Atopy 
Atopy is a personal or familial tendency to produce IgE antibodies in response to low 
doses of allergens, usually proteins, and to develop typical symptoms such as asthma, 
rhinoconjunctivitis, or eczema/dermatitis (Johansson et al. 2001). Furthermore, neither a 
positive skin prick test nor the presence of IgE antibody per se can be a criterion for atopy; 
such patients should be referred to as "skin prick test-positive" and "IgE sensitised", 
respectively. In this work, atopy is defined on the basis of a skin prick test. 
5.3.3 Pathophysiology and pathogenesis of asthma 
5.3.3.1 Methods for evaluation of inflammation
One of the earliest studies of bronchial structure by bronchial biopsies was done by 
Laitinen et al. (1985). Performance of bronchoalveolar lavage (BAL) (Jarjour et al 1998), 
segmental allergen challenge (Makker et al. 1993) or bronchial brushing (Gibson et al 
1993, Vignola 1998) will also reveal more about inflammatory processes in the airways. 
Recently, the use of induced sputum has been confirmed as a research and clinical tool for 
studying inflammation in asthma and COPD (Rytilä 2003). 
5.3.3.2 Inflammatory cells 
An increased number of eosinophils has been found in asthma (Laitinen et al 1992; 1993). 
Eosinophils are the prominent cells in the airway epithelium of patients with symptomatic 
asthma (Bousquet 1990, Laitinen 1992; 1993). The clinical severity of asthma and the 
number of eosinophils in biopsies are correlated significantly (Bousquet et al 1990, 
Laitinen et al 1991). Activation of the eosinophils makes them produce their basic proteins 
such as ECP, eosinophil peroxidase (EPO), and major basic protein (MBP) (Carroll et al 
1992). These proteins, especially ECP and EPO, are cytotoxic, and their levels in induced 
sputum correlate with the severity of asthma and the other markers of asthma (Rytilä 
2002). Eosinophils produce many cytokines, including granulocyte-macrophage colony-
stimulating factor (GM-CSF), interleukin-3, -5 and -6 (IL-3, IL-5 and IL-6), and tumour 
necrosis factor-? and -? (TNF-? and TNF-?) (Barnes 1994). Eosinophils also produce 
potent mediators such as cysteinyl leukotrienes (LTC4, LTD4 and LTE4) and platelet-
activating factor (PAF) (Rodger et al 1997).
Higher numbers of metachromatic mast cells are present in the airways of patients with 
asthma than in healthy subjects (Laitinen et al. 1993). Mast cells produce active mediators 
such as histamine, tryptase, PAF, and prostaglandin D2 (PGD2) all of which are 
bronchospasmic agents in asthma (Wasserman, 1994). Furthermore, an association 
between the severity of asthma and the level of histamine and tryptase in the BAL fuid has 
2121
been documented (Bousquet et al. 1991). Recently, evidence is increasing of the 
important role of mast cells in asthma. Activation of mast cells is one possible mechanism 
in EIB (O’Sullivan et al. 1998). An increased number of mast cells within the smooth 
muscle layer was evident in a group of mainly atopic asthmatics as compared to mast cells 
in those with eosinophilic bronchitis or in healthy controls (Brightling et al. 2002). 
Furthermore, mast cells accumulate in the smooth muscle compartment more in atopic 
than in nonatopic asthma (Amin et al. 2005). 
T-lymphocytes are also involved in the airways of patients with asthma. Activated T-
lymphocytes with increased expression of the cell surface markers occur in the airways. T-
lymphocytes are usually of CD4 type, and the numbers of CD4-type T-lymphocytes are 
correlated with asthma severity (Corrigan et al 1995). Th2-lymphocytes are the major type 
of T-lymphocytes in asthma (Corrigan and Kay, 1992). Th2-lymphocytes produce mainly 
IL-3, IL-4, IL-5, and IL-10, and the products of cytokine by Th1-lymphocytes are interferon-
? (IFN-?), IL-2 and GM-CSF (Chang et al 1990). 
The role of macrophages in the pathogenesis of asthma is still controversial. An increased 
number of macophages expressed as cells/ml have appeared in induced sputum 
(Keatings et al 1997) and in the airway inflammatory infiltrate (Poston et al 1992, Laitinen 
et al 1993) from patients with asthma and COPD than in healthy subjects. In contrast, 
macrophages were not higher in patients with atopic asthma than in healthy subjects 
(Jeffery 1996). Alveolar macrophages capable of producing several cytokines, including IL-
1, IL-6, IL-8, GM-CSF, TNF-? and IFN-? (Kelley, 1990). Potent bronchoconstrictors such 
as cysteinyl leukotrienes, prostaglandins, and leukotriene B4 (LTB4) are also produced by 
macrophages (Lee, 1992). 
Prominent neutrophilic airway inflammation is related to severe persistent asthma 
(Jatakanon et al 1999). Fatal asthma of sudden onset has been demonstrated with 
prominent neutrophilic inflammation in the airway mucosa (Sur et al 1993) and in sputum 
(Fahy et al 1995). Neutrophils are the major cell type in patients with severe asthma who 
are receiving oral corticosteroids (Wenzel et al 1997). Neutrophil numbers and activation 
are also increased in the airways of subjects with noninfectious status asthmaticus 
(Lamblin et al 1998), and neutrophilic inflammation is also evident in COPD. The number 
of neutrophils and the neutrophil granule proteins myeloperoxidase (MPO) and human 
neutrophil lipochalin (HNL) are higher in COPD than in patients with asthma, numbers 
which differed significantly from those of healthy subjects (Keatings et al 1997). Jatakanon 
and colleagues (1999) found higher levels of neutrophils, IL-8, and MPO in patients with 
severe asthma receiving oral steroids than in healthy subjects and in patients with mild 
steroid-naive asthma. Neutrophilic airway inflammation is one possible reason for steroid 
resistance in severe asthma and in COPD (Keatings et al 1997). 
5.3.3.3 Pathogenesis
In atopic persons, genetic and environmental factors can launch the initiation of atopic 
inflammation, and then the major cell type will be Th-2 lymphocytes. Cytokines released by 
Th-2 lymphocytes activate several types of inflammatory cells and encourage inflammatory 
cells to migrate to the bronchus epithelium. Histopathological studies have shown that all 
structures of the bronchi are involved (Haley et al 1998). Bronchial inflammation is 
involved even in mild asthma (Laitinen et al 1993) and presents in both large and small 
airways. These inflammatory processes cause reversible airway limitation and symptoms. 
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The clinical severity of the disease correlates with bronchial inflammation (Bousquet et al 
1990).
A major feature of asthma is epithelial shedding (Laitinen et al 1985, Jeffery et al 1989, 
Laitinen et al 1993). Damage to the epithelium may produce edema in the airways and 
further narrowing of the airway calibre. Airway smooth muscle hyperplasia and 
hypertrophy are regarded as classic histopathologic features of asthma. Remodelling 
processes of the airways are irreversible changes which are characteristics of activated 
inflammatory cells in the airways and changes in the bronchial extracellular matrix with 
thickening of the subepithelial basement membrane (Bousquet et al 1995). 
5.3.4 Treatment of asthma  
Inhaled corticosteroids are the”gold standard” in asthma treatment independent of asthma 
severity. Short-acting beta-agonists as needed should be prescribed for every patient with 
asthma. Combination therapy with ICS and long-acting beta-agonists should be 
considered in patients with moderate to severe persistent asthma (GINA 2007). 
A classification of asthma based on severity is of importance when decisions have to be 
made about asthma management (GINA, 2007). Assessment of asthma based on clinical 
or symptom indices of disease severity has been shown to relate to pathological indices of 
airway inflammation (Bousquet et al 1990). Both the level of airflow limitation and its 
variability enable asthma to be subdivided by severity into intermittent, mild persistent, 
moderate persistent, and severe persistent (GINA 2007). These descriptions of asthma 
severity have been useful because asthma therapy follows a stepwise approach in which 
the level of therapy is increased as the severity of the asthma increases, but recent 
guidelines recommend that asthma treatment is based on asthma control (Figure 7). 
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Figure 7.  Stepwise treatment protocol of asthma according GINA guidelines 
5.4 BHR and asthma therapy 
Treatment with inhaled corticosteroids reduces BHR markedly, and in parallel, it improves 
asthma symptoms (Juniper et al 1990). Furthermore, treatment with inhaled corticosteroids 
improves the structure of the damaged airway epithelium (Laitinen et al 1992) and reduces 
the infiltration of inflammatory cells into the bronchial mucosa, a process which may be 
linked to the reduction in BHR (Boulet et al 2000). These findings support the view that 
BHR and inflammation may be associated.
Short-term effect (rapid effect) has been evident with budenosine; a single dose of 2400 
?g of budesonide has produced a 2.2-fold improvement in BHR to hypertonic saline with a 
simultaneous significant reduction in sputum eosinophils (Gibson et al 2001). A meta-
analysis by van Grunsven and colleagues  (1999) in steroid-naive asthmatics concluded 
that 1000 ?g budesonide or the equivalent reduced BHR on average by 1.16 doubling 
doses compared with placebo within 2 to 8 weeks of treatment, and no clear relationship 
was found between the dose of inhaled steroid and the decrease in BHR. Van Rensen and 
colleagues (1999) observed that a higher dose of FP (1000 ?g) for 4 weeks reduced BHR 
by 1.82 doubling doses compared with placebo.  
Lindqvist and colleagues (2003) examined the effects of 16 weeks of treatment with FP 
250 ?g twice daily of BHR to histamine in 80 patients with newly diagnosed asthma and 
found that PD15FEV1 to histamine increased by 5.2 doubling dose units. A study by 
Hofstra and colleagues (2000) demonstrated that the protection afforded by inhaled FP 
against BHR to methacholine is time- and dose-dependent, whereas protection against 
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EIB is not, which suggests different modes of action of inhaled steroids in protecting 
against these pharmacological and physiological stimuli.
Results of the long-term effect of ICS on BHR are controversial. Ward and colleagues 
(2002) studied BHR to methacholine before and after treatment with high-dose inhaled FP 
750 ?g twice daily, and showed that BHR improved throughout the study year. Some adult 
patients with asthma whose BHR is normalised by ICS therapy can achieve remission 
from disease exacerbation after discontinuation of ICSs. However, patients with severe 
asthma or asthma of long duration may not achieve remission even if their BHR is 
normalised (Tsurikisawa et al. 2008). 
5.5 FENO and asthma 
5.5.1 FENO and asthma diagnostics 
FENO has been shown to discriminate between patients with asthma and from patients 
with chronic cough. The sensitivity and specificity of FENO for detecting asthma were 75% 
and 87%, respectively. The positive and negative predictive values were 60% and 93%. 
The conclusion of that study was that FENO may play a role in the evaluation of chronic 
cough. In that group of patients, low FENO suggested little likelihood of asthma. The 
patients with chronic cough not attributable to asthma showed a low FENO value as 
compared with that of healthy volunteers and asthmatics (Chatkin et al. 1999). One study 
among children showed FENO to be superior to baseline respiratory function and 
bronchodilator responsiveness measured with impulse oscillometry in identifying preschool 
children with probable asthma (Malmberg et al. 2003). 
Conventional tests (spirometry and PEF), FENO, and sputum eosinophils were compared 
in asthma diagnostics. Sensitivities for each of the conventional tests (0-47%) were lower 
than for FENO (88%) and sputum eosinophils (86%). Overall, the diagnostic accuracy with
FENO and sputum eosinophils was significantly greater. FENO measurements and 
induced sputum analysis are superior to conventional approaches, with exhaled nitric 
oxide being most advantageous because the test is quick and easy to perform (Smith et al. 
2004). Another study to identify the sensitivity and specificity of FENO in asthma 
diagnostics showed a specificity for the diagnosis of asthma of 90% and a positive 
predictive value of more than 90%. These findings suggest that the simple and absolutely 
non-invasive measurement of exhaled NO can be used as an additional diagnostic tool for 
the screening of patients with a suspected diagnosis of asthma (Dupont et al. 2003). 
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Figure 8. ROC curve for the measurement of exhaled NO in the diagnosis of asthma. Data 
labels feature different cutoff points of exhaled NO levels. Modified from Dupont et al. 
2003)
Receiver operating characteristic (ROC) curves for the diagnosis of asthma indicate that 
FENO is a robust discriminator between individuals with asthma and healthy subjects and  
data of that study indicate that the choice of expiratory flow rate and collection method can 
be based on practicality and patient comfort without compromising the utility of this test for 
asthma (Deykin et al. 2002). 
5.5.2 FENO and conventional assessment of asthma 
In adult asthma there was no correlation between FENO and values from flow-volume 
spirometry. Only in children with stable asthma was a positive correlation found between 
FENO and percentage change in FEV1 and percentage change in FEF25-75%. A negative 
correlation appeared between prebronchodilator FEV1 and the level of FENO (Colon-
Semidey et al. 2000). Exhaled NO correlated positively with PEF diurnal variability, but 
neither with symptom scores nor beta-agonist use; furthermore, the lack of correlation 
between symptom score and beta-agonist use, FEV1 % of predicted and FENO suggests 
that these measures are reflective of differing aspects of asthma (al-Ali et al. 1998). 
Furthermore, the level of FENO does not correlate with asthmatic symptoms, use of 
rescue medication (ie, short-acting beta-agonist), and variation in PEF (Lim et al. 2000). It 
seems that the association between FENO and conventional assessment is poor. 
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5.5.3 FENO and asthma and atopy 
Patients with atopic asthma have higher levels of FENO than do patients with nonatopic 
asthma (Ludviksdottir et al. 1999), and patients with atopic asthma or rhinitis show higher 
levels of FENO than do nonatopic patients with asthma or rhinitis (Gratziou et al. 1999). In 
the same study, no difference emerged in FENO levels between atopic and nonatopic 
healthy subjects. When asymptomatic, non-smoking healthy subjects have been studied, 
the levels of FENO are higher in atopics than in nonatopics (Horvart et al. 1999). 
Moreover, the FENO level correlates with the number of positive prick tests and total IgE 
level (Ho et al. 2000). Moody and colleagues (2000) have found that the levels of FENO 
are increased in asymptomatic, non-smoking healthy subjects sensitised only to house 
dust mite (HDM) among Pacific islanders, indicating the subclinical allergic inflammation.
The type of sensitisation is important. Atopic subjects monosensitised to HDM, 
independent of having asthma or not, had increased levels of FENO (Barreto et al. 2001).
Sensitisation to perennial allergens in asthma produced increased levels of FENO 
compared with that of asthmatic patients sensitised to seasonal allergens or with 
nonatopic asthma (Olin et al. 2004). Furthermore, levels of FENO are significantly higher 
in patients with asthma who are both sensitised and exposed to a relevant allergen than in 
those who are sensitised but not exposed, and FENO may be a marker of the airway 
inflammation induced by domestic exposure to an allergen in sensitised patients with
asthma (Simpson et al. 1999). Sensitisation to perennial allergens (i.e., cat and house dust 
mite) has been shown to lead to increased levels of FENO in asthma (Langley et al. 2003). 
In atopic children, raised FENO levels are associated with sensitisation to perennial 
allergens, but not to seasonal allergens such as grass pollen. In this population, an 
increase in FENO is associated with BHR and current wheezing, suggesting that FENO is 
more than just a marker for atopy (Leuppi et al. 2002). 
During an allergen challenge test, the levels of FENO have not increased during the early 
phase of the asthmatic reaction, but during the late phase both FEV1 and the FENO level 
have changed significantly (Kharitonov et al. 1995). Moreover, an increase in FENO levels 
is correlated with decrease in FEV1 during the late phase. The baseline level of FENO has 
been found to correlate with the magnitude of the late fall in FEV1 following allergen 
challenge (Deyklin et al. 1998). The levels of FENO were increased during the low-dose 
allergen exposure in asthma when asymptomatic worsening of airway inflammation (i.e., 
increase of sputum eosinophils) occurred (de Kluijver et al. 2002). Gratziou and colleagues 
(2001) have shown that FENO is significantly elevated in patients with seasonal allergic 
rhinitis with and without symptoms, and the levels of FENO are dependent upon whether 
patient had bronchial hyperresponsiveness.
In a study by Lopuhää et al (2003) the increase in FENO after bronchial allergen challenge 
in non-asthmatic rhinitis, in particular in those patients with a dual asthmatic response, 
significantly exceeded the increase in asthma, resulting in similar levels of FENO after 
challenge. After allergen exposure the difference in FENO between non-asthmatic rhinitis 
and asthma at baseline is abolished, due to a significantly greater increase in FENO in 
non-asthmatic rhinitis. Recently, the levels of FENO were found to decrease significantly 
with specific immunotherapy for HDM after 4 months of therapy (Hung et al. 2004). 
In summary, both level and type of sensitisation to allergens are important concerning 
atopy and FENO. 
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5.5.4 FENO and asthmatic inflammation 
Blood eosinophils correlate with the level of FENO both in adults (Salome et al. 1999) and 
in children (Silvestri et al. 1999; Strunk et al. 2003; Franklin et al. 2003) with asthma. In 
children with asthma, only in atopic subjects did a significant correlation between the level 
of FENO and blood eosinophils appear (Franklin et al. 2003; Steerenberg et al. 2003). 
Finally, FENO level has been found to associate with blood eosinophils and the increase in 
FEV1 after a bronchodilatation test in atopic children with asthma (Silvestri et al. 2003). 
The number of eosinophils in sputum and the level of FENO correlate both in adults 
(Jatakanon et al. 1998) and in children (Piacentini et al. 1999; Mattes et al. 1999) with 
asthma. Furthermore, the level of FENO correlates with sputum ECP in children with 
asthma (Mattes et al. 1999). FENO levels have correlated with blood eosinophils within 
both ICS-untreated and ICS-treated groups with asthma, but with sputum eosinophils only 
in ICS-untreated subjects (Reid et al. 2003).
Because FENO correlates closely with percentage of eosinophils in BAL fluid in asthmatic 
children, it is therefore likely to serve as a useful non-invasive marker of peripheral airway 
inflammation (Warke et al. 2002). The level of eosinophils is significantly correlated with 
FENO after treatment with inhaled budesonide in mild asthma (Lim et al. 1999).  Blood 
eosinophil cell counts and FENO levels correlate significantly with the quantity of tissue 
eosinophils in patients with clinical remission of atopic asthma (van der Thoorn et al. 
2001). In contrast, levels of FENO did not correlate with eosinophils from bronchus 
biopsies in a study by Lim and colleagues (2000), involving both steroid-naïve and steroid-
treated asthmatics. Otherwise, a strong and significant correlation between FENO and 
mucosal eosinophilic inflammation appeared in children with difficult asthma, following 
treatment with prednisolone (Payne et al. 2001). 
It can thus be concluded that FENO and eosinophilic airway inflammation have a 
moderate association. 
5.5.5 FENO and BHR 
BHR measured by direct methods (i.e., histamine and metacholine) correlates with the 
level of FENO. In steroid-naïve patients with asthma, FENO level has correlated 
significantly with the PC20 to histamine (Dupont et al. 1998). In a study by de Gouw and 
colleagues (1998) rhinovirus infection has raised FENO levels in asthmatics, an increase 
inversely associated with worsening of airway hyperresponsiveness to histamine. The 
correlation between FENO and PC20 to methacholine suggests that FENO or the 
mechanisms leading to its increase may contribute to airway hyperresponsiveness in 
asthma (Jatakanon et al. 1998). In atopic subjects with asthma, the level of FENO has 
been significantly correlated with the dose-response slope for methacholine, while no such 
correlation appeared in the nonatopic group (Ludviksdottir et al. 1999). Similarly, BHR and 
the number of blood eosinophils both have been positively associated with FENO levels in 
atopic but not in non-atopic children (Leuppi et al. 2002). No correlation appeared between 
FENO and either of two provocative concentrations of methacholine or AMP causing a 
20% fall in FEV1 in patient with allergic rhinitis without asthma (Prieto et al. 2002). These 
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findings suggest that BHR, which is a common phenomenon in asthma, associated with 
the level of FENO in asthma. 
Indirect methods (i.e., exercise, AMP, and mannitol) to measure BHR were associated 
with the level of FENO. A positive correlation between the maximal percent decrease in 
FEV1 after exercise and the baseline FENO value has been found in asthmatic children 
(Terada et al. 2001). Baseline FENO values correlate with the magnitude of postexercise 
bronchoconstriction in children with asthma, suggesting that FENO may be a predictor of 
airway hyperresponsiveness to exercise (Scollo et al. 2000). None of the subjects with 
very low pre-exercise FENO levels (< 12 ppb) demonstrated bronchial 
hyperresponsiveness to exercise, and FENO measurement may obviate the need for 
bronchoprovocation testing in patients who complain of exertional dyspnea (El Halawani et 
al. 2003). However, in clinically well-controlled asthmatics taking inhaled corticosteroids, 
no relationship emerged between markers of airway inflammation (such as exhaled nitric 
oxide and sputum eosinophils) and airway responsiveness to either direct (histamine) or 
indirect (mannitol) challenge. Airway hyperresponsiveness in clinically well-controlled 
asthmatics thus appears to be independent of eosinophilic airway inflammation (Leuppi et 
al. 2001). 
A significant correlation could be established between FENO and responsiveness to AMP, 
but not between FENO and responsiveness to methacholine in patients with clinical 
remission of atopic asthma (van den Toorn et al. 2000). Moreover, despite a significant 
correlation between FENO and PC20 AMP values, no correlation was detected between 
FENO and PC20 to methacholine in patients with asthma monosensitised to Parieta pollen 
(Prieto et al. 2002). Nonatopic subjects with nasal polyposis also have shown higher 
concentrations of FENO than do healthy control subjects, and inhaled AMP has caused 
airway narrowing in a significantly higher proportion of nonasthmatic subjects with nasal 
polyposis than in healthy controls (Prieto et al. 2004). 
The most recent study by Porsbjerg et al. (2008) found that both BHR to mannitol as well 
as to methacholine was associated with elevated markers of airway inflammation: In over 
80% of asthma patients with BHR to mannitol or to methacholine, the FENO level was >20 
ppb. Furthermore, BHR to mannitol was more closely associated with the percentage of 
sputum eosinophils. In addition, there was a stronger correlation between BHR to mannitol 
and the level of FENO compared with BHR to methacholine, indicating that BHR to 
mannitol reflected the degree of airway inflammation more closely than does BHR to 
methacholine in steroid-naïve asthmatics. 
5.5.6 FENO and asthma therapy 
5.5.6.1 Corticosteroids
Early studies dealing with FENO have shown that the level of FENO in steroid-treated 
asthma is similar to that in healthy controls (Kharitonov et al. 1994). The level of FENO 
has also decreased when the dose of inhaled steroids is increased, and a phenomenon 
associated with a reduction in diurnal variability of PEF, and in nocturnal symptoms 
(Kharitonov et al. 1996). Dose-dependent speed of onset of action of budesonide and its 
cessation has occurred in FENO and asthma symptoms in mild asthma (Kharitonov et al. 
2002).
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FENO levels are higher in subjects with difficult asthma than in normal controls, but lower 
than were levels in steroid-naive mild asthmatics (Stirling et al. 1998). Prednisolone-
treated patients have had higher FENO levels than did patients requiring only inhaled 
corticosteroids, suggesting greater disease severity in the former group. This indicates that 
FENO may serve as a useful complement to lung function and symptomatology in the 
assessment of patients with chronic severe asthma, and in the control and rationalisation 
of steroid therapy in these patients (Stirling et al. 1998). 
Furthermore, FENO has been increased in a placebo-treated group after antigen 
exposure; in contrast, treatment with inhaled flunisolide has prevented such an increase in 
FENO in allergic asthmatic children re-exposed to allergens (Piacentini et al. 2000).  
5.5.6.2 Other anti-inflammatory treatments 
Montelukast, a leukotriene antagonist, has been shown to reduce FENO levels in mild 
asthma, an effect that is evident as early as 1 day following start of treatment and 
persisting for 1 week following treatment cessation (Sandrini et al. 2003). Moreover, 
montelukast reduces bronchial hyperreactivity in response to exercise and reduces 
exhaled nitric oxide levels but has little effect on bronchial responsiveness to methacholine 
and adenosine challenges (Berkman et al. 2003). Furthermore, after montelukast 
treatment there occurs a reduction in FENO in asthmatic children receiving maintenance 
therapy with inhaled corticosteroids. This suggests an anti-inflammatory effect of 
montelukast additive to that of inhaled corticosteroids (Ghiro et al. 2002). The combination 
of FP plus montelukast was superior to FP/SM for FENO and PC20 to AMP but was 
inferior for lung function. Thus, in patients taking FP/SM or FP, montelukast conferred 
complimentary effects on surrogate inflammatory markers, effects dissociated from lung 
function (Currie et al. 2003).  However, some studies show no significant effect on FENO 
by montelukast therapy in asthmatic adults (Kanniess et al. 2002) or children (Strauch et 
al. 2003). Furthermore, both fexofenadine and montelukast significantly suppressed the 
levels of exhaled nitric oxide, while only montelukast significantly reduced the peripheral 
blood eosinophil count compared to placebo (Lee et al. 2004). 
In a preliminary study based on FENO measurements, treatment with omalizumab, an IgE 
antibody, may have inhibited airway inflammation during steroid reduction in children with 
allergic asthma; the degree of inhibition of FENO was similar to that seen for inhaled 
corticosteroids alone, suggesting an anti-inflammatory action for this novel therapeutic 
agent in asthma (Silkoff et al. 2004). 
In children with mild-to-moderate asthma no differences have been noted between 
nedocromil and placebo (Covar et al. 2003), and a study of stable asthmatic children 
showed that budesonide, but not nedocromil sodium, significantly reduces FENO even in 
the absence of changes in the lung function (Carra et al. 2001). Gratziou and colleagues 
have shown that FENO is significantly elevated in patients with seasonal allergic rhinitis 
with and without symptoms, and these increased FENO levels can be modulated only by 
inhaled steroids given as anti-inflammatory treatment without any effect on inhaled 
nedocromil (Gratziou et al. 2001). 
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5.5.6.3 Short- and long-acting beta2-agonists
Salbutamol may raise FENO levels in asthmatics taking inhaled glucocorticosteroids. 
Single high-dose salbutamol has not raised FENO levels in asthmatics not taking inhaled 
glucocorticosteroids, but regular use of salmeterol resulted in no change in FENO, either 
used alone or in combination with inhaled glucocorticosteroids (Yates et al. 1997). Nor was 
there any significant difference in another study between the levels of FENO before and 
after inhalation of salbutamol (Colon-Simedey et al. 2000). In asthmatic subjects, 
salbutamol has caused a significant increase in FENO for one hour as compared with 
placebo inhaler. These results suggest that a beta2-agonist may perturb FENO values and 
leads to the recommendation that studies control for that factor (Silkoff et al. 1999). 
Healthy children show no statistically significant differences in FENO values before and 
after inhalation of albuterol, but in children with asthma, FENO values have increased 
significantly from pretreatment and postbronchodilator levels when the effect of spirometry 
and albuterol was studied, suggesting that FENO values should be obtained consistently 
either pre- and at a specific time post-albuterol treatment or spirometry (Kissoon et al. 
2002). Neither montelukast nor salmeterol has affected FENO levels in asthma control 
when given as second-line therapy, but montelukast has produced significant effects on 
AMP challenge, suggesting anti-inflammatory activity (Wilson et al. 2001).  
5.5.6.4 Combination therapy 
Combination inhalers improve pulmonary function without potentiating anti-inflammatory 
effects on exhaled NO and serum ECP as compared with ICS alone (Lee et al. 2003). 
Double the dose of FP alone relative to FP+salmeterol has conferred superior effects on 
FENO but not on lung function (Currie et al. 2003). The levels of FENO and sputum ECP 
showed significant reductions, compared to those of placebo, with formoterol plus 
budesonide or budesonide alone but not with formoterol alone (Aziz et al. 2000). 
5.5.7 FENO and asthma control 
Assessment of FENO after an oral steroid course in patients receiving regular inhaled 
steroid have shown that the levels of FENO correlated with the percentage improvement in 
FEV1 from baseline to the post-steroid, post-bronchodilator value with a FENO level of 
>10 ppb at baseline, having a positive predictive value of 83% for an improvement in FEV1 
(Little et al. 2000) 
The usefulness of FENO for diagnosing and predicting loss of control (LOC) was 
demonstrated in asthma following steroid withdrawal. When comparisons were made 
against sputum eosinophils and BHR to hypertonic saline, correlations were highly 
significant between the changes in FENO and symptoms, FEV1, sputum eosinophils, and 
saline PD15.  Both single measurements and changes in FENO had positive predictive 
values that ranged from 80 to 90% for predicting and diagnosing LOC. These values were 
similar to those obtained using sputum eosinophils and saline PD15 measurements. Jones 
and colleagues (2001) conclude that FENO measurements are as useful as induced 
sputum analysis and BHR in assessing airway inflammation. 
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Recent results suggest that FENO measurements may be useful for monitoring asthma 
patients (Meyts et al. 2003). They found significantly different FENO levels between a 
group of paediatric asthma patients with insufficient and good/sufficient control, as defined 
by clinical assessment (the frequency of use of beta2-agonists, occurrence of day- and 
night-time asthma symptoms, and spirometry results). Recently, a similar result has been 
shown by Delgado-Corcocan and colleagues (2004), evaluating whether FENO levels are 
reflective of asthma severity in childhood asthma and determining the usefulness of FENO 
using the single-breath exhalation technique for monitoring asthma control and compliance 
with steroid treatment. FENO was significantly different in the mild, moderate, and severe 
asthma categories, and levels of FENO correlated significantly with asthma severity, 
compliance, and control. 
The clinical utility of routine monitoring of FENO lies in determining its ability to predict 
future asthma exacerbations compared with other standard clinical measures of 
spirometry, peak flows, quality of life score, medication usage, and symptoms. Those with 
an exacerbation had a higher level of FENO than did those who did not. A nominal logistic 
regression model to determine those variables that predict asthma exacerbation found that 
FENO was the only significant predictor (Harkins et al. 2004). 
A recent study in children with asthma showed that one year of steroid titration on FENO 
did not result in higher steroid doses and did improve airway hyperresponsiveness and 
inflammation (Pijnenburg et al. 2005). Furthermore, in asymptomatic asthmatic children, 
FENO may be an objective predictor of asthma relapse 2 and 4 weeks after 
discontinuation of steroids (Pijnenburg et al. 2005). More recently, a study by Smith and 
colleagues (2005) demonstrated that with the use of FENO measurements, maintenance 
doses of inhaled corticosteroids may be significantly reduced without compromising 
asthma control. These findings support the role of FENO as an additional tool in asthma 
monitoring.
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6 Aims of the study 
The aims of the study were to evaluate: 
1. exhaled nitric oxide levels in healthy subjects and their long-term variation. 
2. short-term variability of exhaled nitric oxide in patients with suspected asthma compared 
to healthy subjects. 
3. short-term effects of inhaled fluticasone on exhaled nitric oxide and bronchial 
hyperesponsiveness in mild asthma. 
4. the association between exhaled nitric oxide, exercise-induced bronchoconstiction, and 
bronchial hyperesponsiveness in patients with suspected asthma. 
5. levels of exhaled nitric oxide and bronchial hyperresponsiveness in patients with 
nonatopic asthma compared with healthy nonatopic subjects and low- and high-sensitised 
atopic asthmatics. 
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7 Methods
7.1 Study populations and designs 
Three hundred and seventy-five subjects participated in the studies, the local ethics 
committee had approved the studies. The main characteristics of the study population are 
shown in Table 2. 
Table 2 Subject characteristics in Studies I - V 
Study Group N Age Males FEV1 Atopy PD15FEV1 EIB
mean (range) N
mean (% 
pred) N mean (SD)
% fall in 
PEF
I Healthy 29 28.6 (21-40) 16 97 - - -
II Healthy 13 27.4 (19-42) 8 95 0 - -
II Respiratory 21 19.7 (19-21) 21 95 13 4.7
symptoms 
II Asthma 10 19.5 (19-20) 10 93 8 15.9
III Asthma 26 36.5 (21-59) 11 81.8 (8.2) 19 0.18 -
IV Asthmatic 181 20 (18-26) 181 94.8 (10) 128 1.5 (1.2) 10.2
symptoms 
V Healthy 10 19.8 (18-22) 10 102.4 (13.8) 0 3.1 (0.28) -
V Asthma 85 20.3 (18-27) 85 93 (9.2) 71 1.00 (1.08) 16.2 (12.7)
7.1.1 Long-term variability in FENO in healthy subjects (Study I) 
The study population consisted of 29 healthy subjects from the Department of Medicine at 
Helsinki University Central Hospital where subjects participated in the phase I study with 
inhaled insulin. Only perfectly healthy subjects were included. Medical history, physical 
examination, clinical laboratory tests (including haematology, clinical chemistry, 
urinanalysis; and human chorionic gonadotropin for female subjects), chest x-ray, and 
ECG were studied. The pulmonary function test included flow-volume spirometry and a 
diffusion capacity test. FENO was performed on the subjects to eliminate any inflammatory 
effect of inhaled insulin. The baseline levels of FENO before inhalation of insulin were 
used and time intervals between FENO measurements were selected according the 
criteria from the phase I study. 
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The main inclusion criteria were BMI < 30, FEV1 > 80% predicted, normal chest x-ray. The 
main exclusion criteria were history of asthma, allergic rhinitis or atopic eczema, use of 
any medication < 7 days before entering the study, and blood donation less than 2 months 
before entering the study. None of the subjects had had a respiratory-tract infection within 
the 4 weeks before entering the study. 
In baseline screening laboratory tests, FENO, spirometry, and diffusing capacity were 
measured on the same day in that order. If subjects met the criteria, the 7-day or 23-day 
variability or both were measured. After 7 days ? 1 day, the next FENO measurement was 
done. After 23 days ? 2 days the final FENO measurement was done. Baseline and all 
other FENO measurements were measured at the same time point (between 7-8 AM). 
7.1.2 Short-term variability of FENO (Study II) 
Thirty-one non-smoking consecutive patients with asthmatic respiratory symptoms were 
recruited to the study; all had a high suspicion of asthma. Only short-acting beta-agonists 
were allowed, and the last dose was taken at least 12 h before the FENO and lung 
function measurements. Asthma was confirmed in ten patients. Diagnosis of asthma was 
assessed by the following criteria: > 15% reversibility of peak expiratory flow (PEF) or of 
FEV1 in bronchodilatation test, or > 20% spontaneous daily variation in PEF compared to 
the mean value of the day, or > 13% fall in PEF or FEV1 after a standardised exercise 
challenge. The 13 healthy subjects were selected from among hospital employees or 
healthy conscripts. They had never smoked and had normal flow-volume spirometry. None 
had had any respiratory-tract infection within the 3 weeks before entering the study. 
All patients were studied with flow-volume spirometry and a skin prick-test in the first study 
(day 1). On day 2 was an exercise challenge. The baseline determination of FENO was 
obtained at 7 to 8 a.m. on the third study day (day 3). FENO determinations were repeated 
at 10 min, 6 h and 24 h after the baseline. A histamine challenge test was performed 
immediately after the last FENO determination on day 4. The healthy subjects were 
studied on two different days. On the first day baseline determination of FENO was 
performed at 7 to 8 a.m., followed by repeated determination of FENO 10 min, 6 h and 24 
h thereafter. Flow-volume spirometry was performed for all healthy subjects after the last 
FENO determination. 
7.1.3 Short-term effect of inhaled fluticasone on BHR (Study III) and peak 
FENO  
The study population comprised of 26 adult patients with mild asthma. Diagnosis of 
asthma was based on ATS criteria (ATS 1991), and the main inclusion criteria were 
PD15FEV1 to histamine of 0.6 mg or less during the run-in period and FEV1 at baseline at 
least 65% of predicted. 
The exclusion criteria were seasonal or unstable asthma, respiratory tract infection or 
exacerbation of asthma during the 4 weeks before entry into the study, current smoking or 
cessation of smoking within the year preceding the study, history of any pulmonary 
disease other than asthma, use of inhaled or oral steroids, inhaled chromones, or 
3535
leukotriene antagonists during the 2 months before the study, use of antihistamines within 
2 weeks or long-acting beta2 agonists within 4 weeks before entry into the study, 
pregnancy or breast feeding, any severe chronic disease, or alcohol or drug abuse. 
The study design was randomised, placebo-controlled, double-blind, and parallel-group. 
During the run-in period of 1 to 2 weeks, the patients continued to take their usual asthma 
medication and recorded daily the asthma symptom score (ranging in daytime between 0 
and 5 and at night between 0 and 4), use of salbutamol (Ventolin MDI, 100 μg, Glaxo 
Wellcome, Germany) and morning and evening PEF values (best of three) using a mini-
Wright peak flow meter (Clement Clarke International, Essex, UK). During the 6-week 
treatment period, the patients inhaled either FP 250 μg MDI (Glaxo Wellcome) or placebo 
twice daily at 12-hour intervals by means of a spacer (Volumatic, Glaxo Wellcome). The 
patients were allowed to use inhaled salbutamol as needed but not within 12 hours before 
measurements of PD15FEV1 and FEV1. No other asthma drugs were permitted. A 
spirometric test, a bronchial challenge with inhaled histamine, and peak FENO were 
performed at baseline, at 6, 12, 24, and 72 hours, and at 2, 4, and 6 weeks after the first 
dose of the treatment regimen. After cessation of treatment (after the last dose) the
measurements were repeated at 48 hours and at 1 and 2 weeks (follow-up). The study 
drugs were administered immediately after the measurements of FEV1, BHR, and peak 
FENO at baseline and at 12, 24, and 72 hours during the treatment period. During the last 
treatment week and the second week after treatment cessation, the patients recorded daily 
their symptoms and PEF as during the run-in period. 
7.1.4 Association between FENO and BHR in asthma (Study IV) 
We studied 181 young male conscripts (18-26 years) referred to the Central Military 
Hospital during 1998 to 2002 because of suspected asthma. Their symptoms included 
dyspnea, wheezing, cough, sputum production, or symptoms related to exercise, all during 
the previous month. They were consecutively included in the study providing that they 
were nonsmokers, had used no inhaled or oral steroids, chromones, or leucotriene 
receptor antagonists during the preceding 2 months, and had no evidence of respiratory 
infections within the preceding 3 weeks. For safety reasons, all subjects had to have 
forced expiratory volume in one second (FEV1) > 70% of the predicted value. Use of 
inhaled short-acting beta-agonists was allowed not less than 12 hours before lung function 
and FENO measurements.
On the first study day, flow-volume spirometry, a bronchodilatation test, and skin prick 
tests were carried out. On the second day, the exercise challenge was performed. FENO 
was measured at 7 to 8 a.m. on the third study day. The histamine challenge was 
performed immediately after FENO measurement. 
7.1.5 Equally elevated concentrations of exhaled nitric oxide in nonatopic 
and low-sensitised atopic asthmatics (Study V) 
The 85 study subjects had been referred to the Central Military Hospital by military 
physicians from various areas in Finland because of  respiratory symptoms including 
dyspnoea, wheezing, cough, sputum production, or symptoms related to exercise during 
the 1 month prior to the study. They were aged 18 to 27 years, with no history of childhood 
asthma, and were recently diagnosed as having asthma according to American Thoracic 
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Society (ATS) criteria: 12% reversibility in FEV1 in spirometry, 15% reversibility in PEF 
after bronchodilator, or 20% daily variability in PEF. In Finland, all conscripts are exposed 
to much outdoor exercise in the forest and thus have a similar exposure to allergens 
(same kind of accommodation, no animal exposure). Conscripts were consecutively 
included in the study if they were lifelong non-smokers, had used no inhaled or oral 
steroids or chromones during the preceding 2 months, and had no evidence of respiratory 
infections within the preceding 3 weeks. Inclusion criteria for FEV1 was >70% of predicted.
Use of inhaled short-acting beta-agonists was allowed not less than 12 hours before the 
FENO and lung function measurements. In addition, 10 non-smoking, nonatopic healthy 
conscripts, who were hospitalised for non-respiratory reasons, volunteered to become our 
control group. 
On the first study day, flow-volume spirometry, a bronchodilatation test, and skin prick 
tests were carried out, and on the second day, an exercise challenge was performed. 
FENO was measured at 7 to 8 a.m. on the third study day. The histamine challenge test 
was performed immediately after the FENO determination. No study measurements were 
performed during the pollen season.  
7.2 Clinical methods 
7.2.1 Exhaled nitric oxide measurement 
FENO was measured with a chemiluminescence analyser (Sievers 270B, Boulder, CO, 
USA). Expiratory airflow and exhaled volume were measured with a pneumotachograph 
simultaneously with FENO in real time, an exhalation procedure performed according to 
European guidelines for exhaled NO measurement (18). Before the measurement, 
patients rinsed their mouths with sodium bicarbonate solution to eliminate any nitric oxide 
(NO) eventually produced in the mouth. For measurements of end-expiratory NO, subjects 
inhaled 100% oxygen (Aga Oy, Riihimäki, Finland) and then, without nose-clips, exhaled 
slowly from total lung capacity over a period of 15 seconds. They exhaled against a flow 
resistor (Hans Rudolph, Model #7100R, 100 cmH20/L/s, flow range 0-0.5 L/s) to close the 
soft palate, thus avoiding any nasal NO contamination. Exhalation flow in the flow window 
was between 0.08 and 0.15 L/s, and the mean individual exhalation flow ranged between 
0.09 and 0.12 L/s. The mean value was recorded for a 3-second period from the end-
exhaled NO plateau. For at least three successive measurements, the mean value was 
recorded for analysis. The acceptable coefficient of variation of a single measurement was 
less than 0.15. 
7.2.2 Peak-FENO measurement (Unpublished data) 
The concentration of nitric oxide in exhaled air was measured with a chemiluminescens 
analyser (Sievers 270B). Expiratory air flow and exhaled volume were measured in real-
time with a pneumotachograph. The sampling rate through the reaction chamber of the 
analyser was 250ml/min for all measurements. The airflow and NO signals were fed 
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through AD and amplifier units to a microcomputer. A software programme for the purpose 
monitored in real time the signals in time domain. 
The analyser was calibrated daily using NO-free oxygen to set absolute zero and then a 
certified concentration of nitric oxide in nitrogen of 184 ppb (AGA Edelgas, Germany). For 
the NO measurements, subjects inhaled pure oxygen and then exhaled from total lung 
capacity after breath holding of 10 seconds with exhalation flow 0.7 to 1.2 l/s. Peak FENO 
levels  were analysed. Results of the analyses were computed and graphically displayed. 
At least three successive recordings were made. The mean values of measurements were 
used as the result. 
7.2.3 Flow-volume spirometry 
FEV1, FVC, and the FEV1/FVC ratio were determined with a flow-volume spirometer 
(Medikro M904, Kuopio, Finland) according to the European Respiratory Society 
guidelines (ERS, 1993), with Finnish reference values for spirometry (Viljanen et al. 1982). 
7.2.4 Pulmonary diffusing capacity 
The pulmonary carbon monoxide diffusing capacity (DLCO) was measured by the single 
breath technique according to the European Respiratory Society guidelines (Cotes et al. 
1993). The DLCO was expressed as an absolute value in mmol/min per kPa and as a 
percentage of the predicted value. The ratio DLCO to alveolar volume (DL / VA) was also 
calculated. Measurement was done with the subject in a sitting position wearing a nose 
clip. Finnish reference values were adapted (Viljanen 1982). 
7.2.5 Histamine challenge 
Bronchial challenge tests were performed by a dosimetric method with controlled tidal 
breathing. An automatic inhalation synchronised jet nebuliser (Spira Elektro 2, Respiratory 
Care Center, Hämeenlinna, Finland) was used for administration of buffered histamine 
diphosphate in a four-step non-cumulative dosage scheme (0.025, 0.1, 0.4, and 1.6 mg). In 
cases where FEV1 did not decrease from baseline by 15% or more after the highest dose, 
an extra dose of 3.2 mg was given (Study III). If FEV1 did not decrease at least 10% after 
the maximum dose of 1.6 mg of histamine, a PD15FEV1 of 3.2 mg served as the final 
result (Studies II, IV-V). The histamine response was measured by use of FEV1
determinations with a wedge spirometer (Vitalograph PF 2, Vitalograph, UK). When FEV1
decreased from baseline by 15% or more after any dose, further administration of 
histamine was discontinued. After the last histamine dose, patients inhaled two puffs of a
short-acting beta2 agonist, salbutamol 200 μg (Ventoline, GlaxoSmithKline, UK) using a 
Volumatic spacer to resolve bronchoconstriction. PD15FEV1 values were calculated from 
logarithmically transformed histamine doses by linear interpolation. 
7.2.6 Exercise test 
A standardised 8-minute running test (Karjalainen et al. 1991) was performed outdoors on 
a 150-meter circular track between 9 and 11 AM. Running speed was adjusted by 
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monitoring each subject’s heart rate with a Sport Tester? PE 3000 heart rate meter (Polar 
Electro Ky, Kempele, Finland). Subjects raised their heart rate to 170 beats /min, 85% of 
the predicted maximal rate, during a 2-minute warm-up, and maintained this rate (165-175 
beats /min) for the remaining 6 minutes of the exercise. PEF values were measured just 
before the exercise and immediately and 5, 10, 20, and 30 minutes after the exercise. Of 
the three successive PEF measurements obtained on each occasion, the highest value 
was recorded for analysis.
The response to exercise challenge was maximum percentage fall in PEF (?PEF%) after 
exercise:  
% fall in PEF = (PEF (baseline) – PEF (after)) / (PEF (baseline) x 100) 
Because the temperature of ventilated air can affect EIB, and the exercise challenge was 
conducted outdoors in temperatures ranging from – 17.5 to + 21.4?C (mean 6.5?C), for all 
exercise challenges we adjusted the ?PEF% according to temperature (6.5?C). In an 
earlier study, the regression coefficient between air temperature and ?PEF% was –0.327, 
calculated from similar exercise challenges in 1809 conscripts with similar symptoms 
(Latvala et al. 2000). 
7.2.7 Diary card 
During the run-in period of 1 to 2 weeks, the patients continued to take their usual asthma 
medication and daily recorded the asthma symptom score (ranging daytime between 0 and 
5 and at night between 0 and 4), use of salbutamol (Ventoline MDI, 100 μg, Glaxo 
Wellcome) and morning and evening PEF values (best of three) using a mini-Wright peak
flow meter (Clement Clarke International, Essex, UK). 
7.2.8 Skin prick test 
Skin tests for assessment of atopy were performed by the prick method with 13 common 
aeroallergens (ALK, Copenhagen, Denmark):  alder, birch, cocksfoot, timothy, mugwort, 
horse, dog, cat, sheep’s wool, house dust mite (Dermatophagoides farinae and D. 
pteronyssinus), alternaria, and cladosporium, and saline as the negative and histamine as 
positive controls. A wheal with a diameter of > 3 mm was regarded as positive, and a 
patient with > 1 positive reactions was regarded as atopic. In Study V, total prick wheal 
sum was calculated by adding the diameters of the wheals of each positive reaction 
excluding histamine (Miles et al. 1995). Subjects with a total prick wheal sum of 3 to 10 
mm were regarded as low sensitised, and those with > 10 mm were regarded as high 
sensitised. 
7.3 Statistical analyses 
There were several statistical points of view in each study, and statistical analyses were 
described separately for different studies. All tests were 2-tailed, with a p-value of less 
than 0.05 considered significant. All analyses were performed with SPSS version 11.0 
(SPSS, Chicago, IL, USA). 
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7.3.1 Long-term variability in FENO in healthy subjects (Study I) 
All data were expressed as means (SD). At baseline, Pearson correlation analysis was 
used to examine the relationship between FENO and age. A two-sided t test was used for 
comparisons between FENO and gender. Long-term variability in FENO was assessed by 
calculating the coefficient of variation ((mean / SD) x 100) intraindividually, and the mean 
CoV was the final result. 
7.3.2 Short-term variability in FENO (Study II) 
Because FENO was skewed, all subsequent analyses were carried out on log-transformed 
data. The difference between levels of FENO in different groups was analysed with one-
way ANOVA and pairwise comparisons were used with the Bonferroni correction. 
The reproducibility of FENO determinations was assessed with those measured after a 10-
min interval by comparing the FENO data obtained at baseline. Intra-class correlation 
coefficients (rI) after 10 min as compared with baseline were calculated for all 
measurements and for each group. The coefficients of variability (CoV) compared with 
baseline at 10 min, 6 h, and 24 h were also calculated. Variability in FENO was assessed 
at 6 h and 24 h after baseline by calculating the difference of means compared with 
baseline. This evaluation was made for each group. A two-sided t-test was used to 
analyse the difference of variability in FENO between groups.  
7.3.3 Short-term effect of inhaled fluticasone on BHR (Study III) and peak-
FENO  
Sample-size calculations were based on the primary variable PD15FEV1. In the groups of 
13 patients a mean difference of 1.0 dose step (SD 0.84) was estimated to have an 80% 
probability of being detected with a t test at a significance level of 5%. The changes in 
PD15FEV1 from baseline were calculated by the doubling dose (DD) technique. The within-
group changes in doubling dose units and the comparisons between the groups were given 
as means with 95% confidence intervals at each time-point. The repeated DD 
measurements were summed by the area under the curve (AUC) method with linear 
trapezoidal application. AUC analysis was split into three successive time segments. The
measurements from 6 to 72 hours were summed to assess the short-term effect of FP 
treatment, and the subsequent measurements from 2 to 6 weeks to assess the long-term 
effect. In addition, after cessation of treatment the changes were summed by the AUC
method; comparisons were made both with baseline and with the last dose of FP or 
placebo.
All AUC values were divided by the total time of each AUC segment to get an average 
level of doubling doses over the time segment (standardised AUC). The standardised AUC 
values in the treatment groups and the differences between the groups were calculated as
means with 95% confidence interval. A t test for independent samples was used to 
compare the standardised AUC values between the treatment groups.
Changes in FEV1 (percentage predicted) from baseline during the trial were also 
calculated using standardised AUC values over the same time segments as for DD units. 
Changes in morning and evening PEF (percentage predicted) from baseline to the last
week of treatment were analysed by a t test for independent samples. The changes in 
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symptom scores and the use of rescue medication were analysed by the Mann-Whitney 
test.
U-
7.3.4 Association between FENO and BHR in asthma (Study IV) 
FENO, PD15FEV1 were skewed and were log10 transformed before analysis to achieve a 
near normal distribution. Exhaled NO levels are reported as medians and 25 to 75%-
quartile range and the other parameters asmean (SD).  Differences between 
anthropometric data, FENO, PD15FEV1, and ?PEF% in the atopic and nonatopic patients 
were analysed with the Mann-Whitney U-test. Mutual correlations between FENO, 
PD15FEV1, and ?PEF% were analysed separately in the atopic and nonatopic groups 
with the Spearman rank test, with 95% confidence intervals calculated. Multiple linear 
regression analyses were undertaken using log (FENO) values as the outcome variable. In 
the first model, the effect of atopy and asthma were evaluated. In the second model, 
?PEF% and log (PD15FEV1) were introduced by a stepwise method, separately. 
Variables in all models were excluded in a stepwise fashion if they did not reach 
significance at the 5% level. 
7.3.5 Equally elevated concentrations of exhaled nitric oxide in nonatopic 
and low-sensitised atopic asthmatics (Study V) 
FENO and PD15FEV1 were skewed and log transformed before analysis to achieve a 
near-normal distribution. FENO and PD15FEV1 levels were reported as medians and 25 
to 75% quartiles, and the other parameters as means (SD). Differences between 
anthropometric data, FENO, PD15FEV1, and severity of EIB in the high-sensitised and 
low-sensitised atopic and nonatopic patients and in healthy controls were analysed with 
ANOVA. ANOVA tests were continued with Dunnett’s test based on two hypotheses: In the 
first, healthy subjects served as the reference group. In the second hypothesis, the high-
sensitised atopic asthma group served as the reference group. A separate comparison 
was made between those with nonatopic asthma and low-sensitised atopic asthma.
Multiple linear regression analysis was undertaken using the log (FENO) value as the 
outcome variable. The model evaluated the severity of EIB (?PEF%), log (PD15FEV1), B-
eosinophils, atopy score, seasonal vs perennial sensitisation, number of positive prick 
reactions, and size of each prick reaction with a stepwise method for atopic patients. 
Variables in the model were excluded in a stepwise fashion if they did not reach 
significance at the 5% level. 
4141
8 Results  
8.1 Long-term variability in FENO in healthy subjects (Study I) 
The mean (SD) value of FENO in all subjects (n = 26) was 6.9 ppb (2.5 ppb). The 95% 
confidence interval was 6.0 to 7.9 ppb. The upper limit of intraindividual variation (+2 SD) 
was 11.9 ppb, and the lower limit (-2 SD) was 1.9 ppb. The mean (SD) value of NO output 
was 39.1 pmol/s (20 pmol/s). We found no correlation between FENO and age (r= -0.06, 
p=0.78). Nor any association between FENO and gender (p=0.40). 
The mean intraindividual coefficient of variation (CoV) within the interval of 7 days was 
15.8% of FENO and 20.7% of NO output. Within an interval of 23 days the mean CoV was 
16.8% of FENO and 18% of NO output. Within an interval of 7 days standard deviation 
was 1.96 ppb, and was 2.4 ppb within an interval of 23 days. 
8.2 Short-term variability in FENO (Study II) 
For variability in FENO, 44 subjects showed a mean (SD) FENO at baseline for all of 16.7 
(23.5) ppb. In healthy subjects (n=13), mean (SD) FENO baseline values were 6.6 (2.3) 
ppb; in patients with respiratory symptoms who did not fulfill the diagnostic criteria of 
asthma (n=21), FENO values were significantly higher 14.6 (11.1) ppb than in healthy 
subjects (p=0.0076). Asthma patients (n=10) had the highest mean (SD) FENO levels, at 
34.2 (43) ppb, as compared with healthy subjects (p<0.001) or patients with respiratory 
symptoms (p=0.02) (Table 3). 
The intra-class correlation coefficient (rI) was 0.955 for all measurements between 
baseline and after 10 min. The rI was 0.959 in healthy controls, 0.986 in the respiratory 
Table 3 Exhaled nitric oxide (ppb) and its short-term variability in different groups 
during the study 
Baseline SD 10 min CoV 6 h CoV 24 h CoV
mean (ppb) mean % mean % mean %
Healthy subjects 6.6 2.3 6.7 5.1 6.5 10.8 5.8 11.7
Respiratory symptoms 14.6 11.1 15 7.1 14.7 16.4 14.5 22.2
Asthma   34.2 43 32.7 13.5 33.3 19.4 32.8 26.4
ppb = parts per billion, SD = standard deviation, CoV = 
Coefficient of variation 
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symptoms-group, and 0.936 in asthmatics. The mean difference in FENO after 10 min 
compared with baseline was 0.18 ppb (Fig. 1). The CoV of FENO after 10 min, 6 h, and 24 
h was good (Table 3). 
8.3 Short-term effect of inhaled fluticasone on BHR (Study III) and on 
peak FENO
8.3.1 Short-term effect of inhaled fluticasone on BHR
The increase in PD15FEV1 from baseline was greater in the FP group than in the placebo 
group. The short-term difference between the treatment groups in 6 to 72 hours was 
significant (p=0.048), and the effect was sustained until the end of the treatment period (2–
6 weeks, Table 4 and Figure 9). In the FP group, the PD15FEV1 between 72 hours and 6 
weeks after the start of treatment was 1.85 to 2.07 doubling doses above baseline level, 
and the difference between the treatments during that period was 1.19 to 1.98 doubling 
doses. At the end of the 6-week treatment period the geometric mean PD15FEV1 in the FP 
group was 0.510 mg (range 0.061–2.369) and in the placebo group 0.248 mg (range 
0.003–1.912).
After cessation of treatment, the effect of FP on BHR diminished significantly within 2 
weeks (Figure 9). At the end of the 2-week follow-up PD15FEV1 had returned to near 
pretreatment levels in the FP group (0.85 doubling doses above baseline). The geometric 
mean PD15FEV1 at the end of the 2-week follow-up period was 0.294 mg (range 0.042–
1.925) in the FP group and 0.280 mg (range 0.014–1.827) in the placebo group. 
FEV1 (percentage predicted) did not increase significantly from baseline in the FP group 
compared with the placebo group within 72 hours (mean change 2.9%v 0.3%, p=0.084), 
but the long-term effect was significant (mean difference from 2 to 6 weeks 3.8%v -0.3%, 
p=0.028). No statistically significant differences were seen between treatment groups in 
the PEF values recorded at home. Morning PEF values increased 2.4% and evening 
values 2.5%, in the FP group, with a corresponding decrease of 0.4% and 0.5% in the 
placebo group. Symptom scores or the use of rescue medication between the groups did 
not significantly differ during or after treatment. 
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Table 4 Mean (95% CI) changes in PD15 FEV1 values in doubling doses (DD) 
compared with baseline in fluticasone propionate (FP) and placebo groups
and mean (95% CI) differences between groups
Time from treatment onset Fluticasone (n=13) Placebo (n=13) Difference (FP v placebo) 
Treatment v baseline
6 hours 0.58 (-0.07 to 1.22) 0.63 (-0.17 to 1.43) -0.06 (-1.03 to 0.92) 
12 hours 1.26 (0.70 to 1.82) 0.43 (-0.26 to 1.12) 0.83 (-0.01 to 1.67) 
24 hours 1.75 (1.08 to 2.43) 1.03 (0.47 to 1.60) 0.72 (-0.12 to 1.56) 
72 hours 1.98 (1.33 to 2.63) 0.79 (-0.11 to 1.70) 1.19 (0.13 to 2.25) 
2 weeks 1.92 (1.07 to 2.77) 0.59 (-0.16 to 1.34) 1.33 (0.26 to 2.40) 
4 weeks 1.85 (0.88 to 2.82) 0.58 (-0.15 to 1.31) 1.27 (0.12 to 2.42) 
6 weeks 2.07 (1.30 to 2.83) 0.09 (-0.64 to 0.81) 1.98 (0.98 to 2.98) 
Post-treatment v baseline
48 hours 1.47 (0.32 to 2.61) 0.66 (-0.12 to 1.45) 0.81 (-0.48 to 2.09) 
1 week 1.15 (0.01 to 2.29) 0.11 (-0.74 to 0.96) 1.04 (-0.29 to 2.3) 
2 weeks 0.85 (-0.57 to 2.27) 0.26 (-0.37 to 0.89) 0.59 (-0.82 to 2.00) 
Post-treatment v 6 weeks
48 hours -0.40 (-1.00 to 0.20) 0.43 (-0.04 to 0.90) (-0.83 (-1.54 to -0.12) 
1 week -0.72 (-1.34 to -0.09) -0.12 (-0.72 to 0.48) -0.60 (-1.41 to 0.22) 
2 weeks -1.02 (-2.19 to 0.16) 0.03 (-0.58 to 0.63) -1.04 (-2.25 to 0.17) 
Post-treatment values are compared with those at baseline and at 6 weeks (last dose). n =11 in the FP group and n =12 in the placebo group in 
the post-treatment period at 48 hours, 1 week and 2 weeks.
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Figure 9. Time-course of the effect of inhaled fluticasone propionate (FP) 250 μg twice 
daily (n=13) or placebo (n=13) on bronchial hyperresponsiveness (BHR) in patients with 
mild asthma. Changes in BHR are presented as mean changes in PD15FEV1 for histamine 
expressed as doubling dose units compared with baseline PD15FEV1 values. Patients 
were treated with FP for 6 weeks and followed for 2 weeks after cessation of treatment; p 
values indicate significant differences between the FP and placebo groups from 6 to 72
hours (p=0.048) and from 2 to 6 weeks (p=0.007) (area under the curve analysis). 
L=baseline.
term effect of inhaled fluticasone on peak FENO (unpublished 
data) 
0.7
ak-
e
O levels were 
till significantly lower the FP group compared to the PL group (p=0.04). 
 and peak FENO during the 
treatment period, the correlation was r = - 0.44 (p=0.0007). 
B
8.3.2 Short-
At baseline, the geometric mean of peak FENO was 59.9 ppb in the FP group and 9
ppb in the PL group. After 2-week treatment, peak FENO decreased from baseline 
significantly more in the FP group than in the PL group (-54.7% vs. -5.9%, p=0.01). Pe
FENO levels remained stable during the rest of the treatment period.  The differenc
between groups (FP minus PL) was -15.9 at week 4 (p=0.10) and -14.1 at week 6 
(p=0.07). At follow-up peak-FENO levels were slowly increased in the FP group, with no 
change in the PL group. After 1 week of cessation of treatment peak-FEN
s
After 2-week treatment, a positive correlation appeared between the within-subject 
changes in PD15 (as doubling doses) and peak FENO (as% changes, r= -0.52 (p=0.008)
(Figure 10). Including all the repeated observations of PD15
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Figure 10. Correlation between changes in PD15FEV1 and changes in peak FENO after 2 
weeks of treatment with fluticasone propionate (unpublished data) 
8.4 Association between FENO and BHR in asthma (Study IV) 
In atopic patients, level of FENO was on average over twice that of nonatopic patients 
(Table 5). In atopic patients, EIB was slightly but significantly more severe, but their BHR 
in histamine challenge did not differ significantly from that of nonatopics (Table 5). When 
atopic and nonatopic patients with a confirmed diagnosis of asthma were analysed, there 
was no difference in either EIB or HIB between the groups (Table 5). 
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Table 5 Exhaled nitric oxide, exercise-induced bronchoconstriction and
histamine-induced bronchoconstriction in young male patients 
All atopic Atopic All nonatopic Nonatopic
patients asthmatics patients asthmatics
n = 128 n = 68 n = 53 n = 19
FENO, ppb # 21.2 (13.2 - 44.6)*** 29.6 (18.4 - 52.0)¤¤¤ 10.2 (8.4 - 14.8) 12.4 (8.5 - 20.0)
?PEF% ## 11.2 (10.8)** 16.6 (12) 7.1 (7.4) 12.3 (9.3)
PD15FEV1, mg # 1.0 (0.4-2.5) 0.4 (0.2-1.0) 1.5 (0.5-3.2) 0.4 (0.2-0.7)
NOexp: exhaled nitric oxide; PD15FEV1: provocative dose of histamine causing a 15% fall in FEV1; 
?PEF%: fall in PEF after exercise challenge; # : median (25 -75% quartiles), ## : mean (SD)
atopics vs nonatopics: ** p < 0.01; *** p < 0.001
atopic asthma vs nonatopic asthma: ¤¤¤ p < 0.001
In atopic patients, FENO correlated significantly with both EIB and HIB (Table 6 and Figure 
11).  In contrast, in nonatopic patients, FENO did not correlate with BHR measured by 
either an indirect or direct method. A multiple linear regression model showed that atopy (p 
< 0.001), severity of EIB (p <0.001), and severity of HIB (expressed as log PD15FEV1) 
(p=0.006) all significantly associated with FENO (Table 6). A significant interaction 
occurred between atopy and severity of EIB, as well as atopy and HIB; therefore, separate 
regression models were constructed for atopic and nonatopic patients. In these models, 
the severity of EIB and HIB was associated with FENO in atopic but not in nonatopic 
patients. These results did not change even when only patients with confirmed diagnosis 
of asthma were analysed. 
Table 6 Variables included in multiple linear regression model 
with log (FENO) as the dependent variable in all patients (n = 181)
Variable B 95% CI p value partial 
correlation
Atopy 0.517 0.293 to 0.742 < 0.001 0.323
?PEF% 0.028 0.016 to 0.039 < 0.001 0.335
log (PD15FEV1) -0.128 -0.219 to -0.037 0.006 -0.204
B = regression coefficient; CI = confidence interval; ?PEF%: maximum percentage fall in 
PEF after exercise challenge; PD15FEV1: provocative dose of histamine causing a 15% 
fall in FEV1 
Partial correlation = correlation between dependent and each independent variable 
taking into account the other variables in the model
Adjusted coefficient of determination (R2) for all variables is 0.32
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Figure 11 Association between exercise-induced bronchoconstriction (EIB,% fall in PEF) 
and exhaled nitric oxide (FENO, ppb) in atopic patients. The curve is exponentially fitted. 
Rsq = r2 (coefficient of determination) 
F
8.5 Equally elevated concentrations of exhaled nitric oxide in 
nonatopic and low-sensitised atopic asthmatics (Study V) 
Based on the skin prick test, 71 (84%) of the subjects were atopic and 14 (16%) nonatopic. 
Of those atopic, 58 (82%) were high-sensitised (total prick wheal sum >10 mm) and 13 
(18%) low-sensitised (total prick wheal sum 3 to 10 mm). FENO levels and degree of BHR 
in the study groups are shown in Table 7 and Figures 12 and 13. The median FENO of the 
high-sensitised atopic patients was more than double that of the nonatopic asthmatics. 
Low-sensitised and nonatopic asthmatics had similar FENO levels, with FENO level 
regarded as elevated if it exceeded 12 ppb. Elevated levels appeared in 57% of subjects 
with nonatopic asthma, while this level was exceeded by 71% of subjects with low- and 
91% with high-sensitisation atopic asthma. 
FEV1 of predicted was slightly higher in subjects with low-sensitisation atopic asthma than 
in nonatopic asthma. BHR to histamine and to exercise between subjects with nonatopic 
asthma and with low-sensitisation atopic asthma was similar, but high-sensitised atopic 
asthmatics had significantly more severe BHR to both histamine and exercise than did 
nonatopic asthmatics (p < 0.05, both comparisons) (Table 7). 
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Table 7  Exhaled nitric oxide and bronchial responsiveness to histamine and to exercise in study groups
Healthy Nonatopic Low-sensitized High-sensitized
subjects asthma atopic asthma atopic asthma
n = 10 n = 14 n = 13 n = 58
FENO, ppb median (25 -75% quartiles) 6.5 (5.1 - 8.0)§§§ 15.2 (9.7 - 24.7)***§§§ 16.7 (10.8 - 25.6)***§§ 34.9 (21.3 - 53.8)***
PD15FEV1, mg median (25 -75% quartiles) - a 0.82 (0.38 - 3.2)§ 1.1 (0.59 - 1.1)§§ 0.37 (0.16 - 0.96)
PD15FEV1 <1.6 mg % of subjects 0 57 43 86
PD15FEV1 <0.4 mg % of subjects 0 29 14 53
EIB,% fall in PEF mean (SD) ND 10.3 (7.7)§ 12.3 (6.8) 18.6 (14.1)
EIB,% fall in PEF > 10% % of subjects ND 36 69 78
FENO: exhaled nitric oxide; PD15FEV1: provocative dose of histamine causing a 15% fall in FEV1;  
EIB: exercise-induced bronchoconstriction; and ND: not done.
* p < 0.05, ** p < 0.01, *** p < 0.001 compared to healthy subjects.
§ p < 0.05, §§ p < 0.01, §§§ p < 0.001 compared to high-sensitized atopic asthma.
a  all values over 1.6 mg (no bronchial hyperreactivity).
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Figure 12. Boxplot presentation of the distribution of exhaled nitric oxide (FENO) in the 
groups (circles are outliers and asterisks are extreme values). 
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Figure 13. Boxplot presentation of the distribution of PD15FEV1 in the groups (outliers are 
circles) (unpublished data). 
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9 Discussion
9.1 Study population and methods 
9.1.1 Study population 
In Study I, healthy subjects were carefully evaluated from the phase I study with inhaled 
insulin (see Methods). Atopy was evaluated regarding their medical history. We did not 
perform the skin prick tests or measurements for specific IgE to exclude possible hidden 
allergy. Measurements of FENO were performed during winter time and timing of 
measurement eliminated the possible effect of seasonal allergic rhinitis. However, study 
subjects in Study I were healthy and examined carefully. 
Study III comprised 26 adult patients with mild asthma diagnosed based on ATS criteria. In 
short, we studied steroid-naïve, non-smoking asthma patients with mild to moderate BHR 
to histamine. The mean PD15FEV1 was 0.18mg, which indicated room for PD15FEV1 to 
increase during the treatment with FP. However, the duration of the disease in most of the 
patients had been more than 2 years. Although the disease was persistent, its severity was 
mild based on low symptom scores, only slightly (if any) reduced lung function, and limited 
use of rescue medication.
Our study population of non-selected male conscripts (II, IV-V) was very homogenous: 
They were of the same age, were nonsmoking and steroid-naive, and all had respiratory 
symptoms suggesting asthma, but had no other interfering diseases. Such a population is 
most suitable for evaluation of airway inflammation and airway reactivity. As all the 
patients had symptoms suggesting asthma, we also included those patients who did not 
fulfill the standard criteria of asthma, in order to obtain a wider range of variety in airway 
inflammation and bronchial hyperresponsiveness (IV). The main results did not change 
when only those patients with an unequivocal diagnosis of asthma underwent analysis. 
The study population of 181 patients was sufficiently large for assessment of the 
differences between atopic and nonatopic groups. Study V included only patients with 
asthma followed by ATS criteria. 
9.1.2 Methodological considerations 
9.1.2.1 FENO measurement 
In the present series of investigations (Studies I-II and IV-V) the measurement of FENO 
was made according to the ERS guidelines. Furthermore, the exhalation flow was 
restricted to the range in the flow window between 0.08 and 0.15 L/s. Actual individual 
exhalation flow was maintained between 0.09 and 0.12 L/s. Limitation of exhalation flow 
rate minimises variation in FENO (Silkoff et al. 1997). Our measurements of FENO started 
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in 1998, and ATS guidelines for FENO measurements were published in 1999; for that 
reason we did not change methodology during the study. The preliminary study by 
Zetterquist and colleagues (1999) showed that ingestion of a meal rich in nitrate prior to 
FENO measurement raised the level of FENO. When the mouth is rinsed with a basic 
solution or anti-bacterial solution, the increase in FENO can be eliminated. Our method 
included mouth rinsing before measurement, so this possible contamination could be 
eliminated. We also did measure FENO before lung function tests (including histamine 
challenge), because repeated spirometry and measurement of BHR could influence FENO 
(Silkoff et al. 1999). We measured FENO the day after the exercise challenge for practical 
reasons, besides the effect of exercise on airway inflammation or HIB has been 
considered negligible (Gauvreau et al. 2000). 
Unfortunately, we did measurements of FENO according to ERS guidelines, not according 
to ATS, and this makes comparison of the results with ATS guidelines from other 
investigators challenging.  Moreover, the criteria of reproducibility were stricter than with 
our method. Repeated reproducible exhalations should be performed, resulting in three 
NO plateau values that agree within 10% of the mean value. Exhaled NO is then 
calculated as the mean of these three values.  
Peak FENO measurements were done in Study III. The first patients were randomised to 
the study in the beginning of 1996. After that, the measurement of FENO has been 
developed in different ways. At the present time, the knowledge of FENO measurement 
has increased logarithmically compared to that in 1996. Many weaknesses emerged in 
peak FENO methodology: using the nose clip, breathholding, no standardised exhalation 
flow, and no use of the resistor. Because of high variability in peak FENO, the results of 
the peak FENO in Study III were not included in the final manuscript. 
9.1.2.2 BHR measurement 
Histamine challenge tests were performed by a dosimetric method with controlled tidal 
breathing (Sovijärvi et al. 1993). PD15FEV1 values were calculated from logarithmically 
transformed histamine doses by linear interpolation. The method was carefully validated 
and had good reproducibility (Sovijärvi et al. 1993). In cases where FEV1 did not decrease 
from baseline by 15% or more after the highest dose, an extra dose of 3.2 mg was given 
(Study III). If FEV1 did not decrease at least 10% after the maximum dose of 1.6 mg of 
histamine, PD15FEV1 of 3.2 mg served as the final result (Studies II, IV-V). If FEV1 did 
decrease at least 10% but less than 15% after the maximum dose of 1.6 mg of histamine, 
the PD15FEV1 were calculated by linear interpolation (Cockroft et al. 1983). In this way, 
we were unable to calculate the exact PD15FEV1, and this therefore had a possible effect 
on the results. However, the number of patients with PD15FEV1 more than 1.6 mg were 
quite few.
9.1.2.3 Exercise test 
We used a standardised 8-minute running test outdoors with adjusted heart rate 
monitoring (Karjalainen et al. 1991). PEF values were measured just before the exercise 
and immediately and 5, 10, 20, and 30 minutes after the exercise. An 8-minute running 
test has been shown to be adequate long for evaluation of EIB and using the shorter test 
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time, the severity of EIB might be lower. We used PEF measurements for evaluation of the 
severity of EIB; recent guidelines, however, recommended FEV1 (ATS 1999) 
measurement. PEF measurements in the exercise test served as the standard method for 
more than 20 years at the Central Military Hospital. We did not measure ventilation during 
the exercise test but did measure heart rate. There were studies showing that intensity, 
duration, mode, and environmental conditions during exercise must all be considered. 
While historically the exercise challenge has been prescribed at an intensity of 85% 
maximum heart rate (Andersson et al. 1971), recent studies suggest that a significantly 
higher exercise intensity should be used (up to 95 to 100% of maximum effort), especially 
in the athlete population (Rundell et al. 2000). The duration of 6 to 8 minutes of exercise is 
consistent with a mathematical model of airway drying (Anderson and Daviskas 1997). 
However, a successful diagnosis has been obtained using short-duration; high-intensity 
exercise.The 2-minute challenge described by Rundell and colleagues (2000) for speed 
skaters is a high-intensity, high-ventilation exercise that sufficiently dries the airways to 
provoke a response in susceptible individuals within 2 minutes.  
We were advised about the seasonal variability in EIB outdoors (Karjalainen et al. 1989), 
and therefore did not include patients in the study during the high pollen season.  
Temperature and air humidity affect EIB severity (Rundell et al. 2000). We adjusted the 
severity of EIB according to temperature in Studies IV and V. For adjustments, the data for 
temperature and relative humidity during the study hours were collected from the database 
of the Finnish Meteorological Institute. Absolute air humidity was computed according to a 
study (Latvala et al, 2000) using the same exercise challenge method in the same place 
and with similar subjects: 1809 army conscripts with suspected asthma. This method has 
shown a significant linear dependence of % PEF on temperature (?C) and water content of 
the air (H2O / m3). The regression coefficient used with respect to absolute air humidity 
was -1.026, and that with respect to air temperature was -0.327. 
9.1.2.4 Determination of atopy 
Skin prick tests for assessment of atopy were performed with 13 common aeroallergens: 
alder, birch, cocksfoot, timothy, mugwort, horse, dog, cat, sheep’s wool, house dust mites 
(Dermatophagoides farinae and D. pteronyssinus), and the fungi Alternaria, and 
Cladosporium, with the solvent as the negative and histamine as the positive control. A 
wheal with a diameter of at least 3 mm in the presence of expected reactions to the control 
solutions was regarded as a positive reaction, and subjects with at least one positive 
reaction were regarded as atopic. Total prick wheal sum was calculated by addition of the 
diameters of the wheals of each positive reaction excluding histamine. Subjects with a total 
prick wheal sum 3 to 10 mm were regarded as low sensitised, and those with >10 mm 
were regarded as high sensitised (Study V). 
These are the major allergens in Finland, and according to the results from the Skin and 
Allergy Hospital, more than 90% of atopics can be found with these allergens (Leena 
Petman and Tari Haahtela, oral communication). We did not measure specific IgE levels, 
and there was only a low possibility for hidden allergy in nonatopic patients. 
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9.2 Primary findings and their relation to Studies I – V 
9.2.1 Long-term variation in FENO in healthy subjects 
FENO was unrelated to age or sex in healthy subjects, and we found no significant long-
term variability in FENO. Age-related changes in FENO have been reported in healthy and 
in asthmatic children (Franklin et al. 1999; Malmberg et al. 2003), but we found no 
significant correlation between age and FENO in adults. An association between FENO 
and height has been found in several studies (Olin et al. 2006, Bohadana et al. 2008). 
Obesity can change the levels of FENO (Busia et al. 1999), but in the present study all 
subjects had BMI less than 30. Menstrual cycle has affected the long-term variability at 7 
days in female subjects (Kharitonov et al. 1994; Morris et al. 1996), but long-term 
variability at 23 days was measured at almost the same cycle phase, and changes in 
hormone levels between measurements were not very large. 
In several studies, atopic asymptomatic subjects appeared to have higher FENO than did 
nonatopic asymptomatic subjects (Horváth and Barnes 1999, Franklin et al. 2004 and Olin 
et al. 2007). After critical evaluation, all these studies had one or more weakness in their 
patient selection: Patients with BHR to methacholine had previous asthma, or atopy was 
defined by increased IgE level only. The most recent finding showed that an atopic 
constitution defined as positive skin prick test results does not elevate FENO in healthy 
nonsmoking adults with no signs or symptoms of airway disorders, meaning that the same 
reference ranges for FENO can be applied to both skin prick test-positive and -negative 
subjects (Rouhos et al. 2008). 
These results suggest that FENO measurement was reproducible, and the levels of FENO 
were less than 12 ppb in healthy subjects. We found no significant long-term variability in 
FENO in healthy subjects. 
9.2.2 Short-term variation in FENO in healthy and asthmatic subjects 
This study showed that in young men with asthma or asthma-like symptoms as well as in 
young healthy adults, determination of exhaled NO is reproducible. Patients with 
respiratory symptoms who did not fulfil the diagnostic criteria of asthma had FENO values 
significantly higher than in healthy subjects, but significantly lower than in asthma patients. 
This finding support results showing that patients with respiratory symptoms suggesting 
asthma but with normal lung function had a higher number of sputum eosinophils than did 
healthy subjects (Rytilä et al. 2000), but the degree of eosinophilic inflammation was less 
pronounced than in asthmatics. Furthermore, Lehtimäki and colleagues (2005) have 
shown that both the bronchial and alveolar components of FENO were increased in 
patients who did not fulfil the diagnostic criteria of asthma compared with those of healthy 
subjects.
In all groups studied, short-term reproducibility after the 10-min interval was good. The 
intra-class correlation coefficient was 0.95, which was similar to previous findings of rI
>0.92 (van Rensen et al. 1999) and 0.98 in one population study (Salome et al 1999). 
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Knowledge of short-term reproducibility of FENO in asthma was scant. An rI of 0.81 in mild 
to moderate asthmatics was used by de Gouw and colleagues (1998). A mean difference 
of 0.094 ppb between the two closest FENO values has been reported (Gabbay et 
al.1998). In our study, the mean difference in FENO after 10 min compared with baseline 
was 0.08 ppb in healthy subjects and 0.18 ppb overall, including in patients with asthma. 
Coefficients of variation (CoV) have been 19% in healthy subjects and 10% in asthmatics 
after a 10-min interval (ten Hacken et al 1998).
Previously, FENO measured with a flow of 250 mL/s at different airway pressures, found 
CoV to be 6% (Högman et al. 1997).In our study, the variation in FENO in healthy subjects 
was 5.1%, lower than in previous reports. In our study, variation in FENO in asthmatics 
was similar to that previously reported (ten Hacken et al 1998). The most recent study 
showed FENO levels to be stable during repeated measurements (intraclass correlation 
coefficient, 0.81) in healthy, nonsmoking African-Americans (Levescue et al. 2008). 
CoV values for FENO within the interval of 6 h and 24 h in healthy subjects or in patients 
with asthma-like symptoms or with asthma did not mutually differ. An intra-day variation 
(CoV) of 8.6 to 11.1% and inter-day variation of 19.0 to 23.2% at different expiratory flows 
have been shown in healthy subjects (Silkoff et al. 1998). We found no circadian variation 
in FENO in any group; however, we did not measure FENO during the early morning (i.e., 
4 a.m.). Previously, a circadian variation in FENO showed that FENO was significantly 
decreased at 4 a.m. as compared with 4 p.m. in nocturnal asthma (ten Hacken et al. 
1998). No circadian rhythm occurred in the study with healthy children measured on 6 
consecutive days, but their FENO showed an intra-individual coefficient of variation of 
25.9%. In a two-compartment model of the lung, the alveolar NO concentration was 
constant with age, whereas the airway part of NO steadily increased with age (Latzin et al. 
2002)
In a recent study, FENO, according to ATS guidelines, was measured on 5 consecutive 
days (four measurements on the same day) for adults and twice on the same day for 
children. In both children and adults the coefficient of reproducibility was 2.11 parts per 
billion (ppb), and the intraclass correlation coefficient was 0.99. No diurnal or day-to-day 
variation occurred, nor any learning effect, and the results of FENO measurements were 
identical at the beginning and at the end of the study (Kharitonov et al. 2003). The most 
recent study demonstrated that the reproducibility of FENO is not influenced by gender or 
smoking status in subjects refraining from smoking before FENO assessment, and it 
provided evidence that FENO is potentially useful in the survey of populations, only fairly 
small samples being necessary to assess significant changes in FENO levels (Bohadana 
et al. 2008). 
According to the results of our study and from other studies, measurement of exhaled nitric 
oxide by use of a standardised method based on ERS suggestions was well reproducible 
over a short period in the short term in healthy subjects, in patients with asthma-like 
symptoms, and in mild asthma. 
9.2.3 Short-term effects of FP on BHR and peak FENO in mild asthma 
The hourly or daily changes in BHR after the start or cessation of treatment with ICS have 
not been studied. No data are available on how rapidly a sustained reduction in BHR can 
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be obtained after starting ICS treatment. In the present study, the BHR in terms of 
PD15FEV1 for histamine was reduced and reached a plateau within 72 hours of starting 
treatment. The maximal effect occurred within 6 weeks. A significant improvement was 
also found in FEV1 within 6 weeks of commencing FP treatment. Most of the treatment 
effect on BHR disappeared within 2 weeks of cessation of treatment. 
These results are line with previous findings, as Van Rensen and colleagues (1999) 
observed that a higher dose of FP (1000 μg) for 4 weeks reduced BHR by 1.82 doubling 
doses compared with placebo, the effect being similar to that found in our study. Another 
study showed the effect of a high dose of FP (2000 μg), at 2-week intervals for testing 
BHR;  the maximum reduction of 1.9 doubling doses of methacholine was achieved after 6 
weeks of treatment (Convery et al. 2000). The maximum effect in the present study at 6 
weeks was similar, but obtained with a much smaller dose. Furthermore, Vathenen et al. 
(1991) found a significant effect on BHR in adults with a single dose of 800 μg budesonide 
after 6 hours, and Sherrington and Mallol (1999) reported a significant effect in children 
with a single dose of 2000 μg budesonide or 400 μg fluticasone after 8 hours. The effect of 
the single dose disappeared after 12 hours. Furthermore, Gibson and colleagues (2001) 
demonstrated a significant reduction in BHR to hypertonic saline in 6 hours with a large 
(2400 μg) single dose of budesonide. These results, together with ours, suggest that a 
higher dose of ICS can relieve BHR faster than a low dose (i.e., in a dose-dependent 
manner).
A short-term effect from ICS on BHR is linked to a reduction in airway inflammation. A 
single dose of budesonide reduced bronchial responsiveness to hypertonic saline 
concomitantly with a reduction in sputum eosinophils but not in mast cells (Gibson et al. 
2001). Interestingly, a reduction in FENO occurred with lower doses of ICS than the 
decrease in BHR to methacholine (Jatakanon et al. 1999). FENO has been shown to be 
correlated with BHR in many studies of steroid-naive asthmatics, reflecting the role of BHR 
as an indirect marker of airway inflammation (Dupont et al. 1998; Jatakanon et al. 1998). 
ICS reduce FENO in a dose-dependent manner, the effect starting within 3 to 5 days after 
start of treatment (Kharitonov et al. 1996). In our study, a significant correlation between 
reduction of BHR and fall in peak FENO emerged after 2 weeks of treatment with FP 
(unpublished data). 
The reversal of BHR after cessation of treatment may be dose-dependent, but the 
evidence for this is scanty. Gershman and colleagues (2000) found that, after a 6-week 
treatment period with FP, BHR reversed within 3 days when the daily dose was small (100 
μg) but within 2 weeks after treatment with a higher dose (1000 μg). We observed a 
significant reversal of BHR in 2 weeks after cessation of 6 weeks of treatment with FP 500 
μg daily; at that time BHR returned to near pretreatment levels. 
Our study was designed to evaluate short-term effects of ICS on BHR, but evidence that 
monitoring BHR during long-term treatment for adjustment of the corticosteroid dose in 
asthma has been clinically useful. When corticosteroid treatment was adapted by 
assessing BHR to methacholine, patients suffered about half the exacerbations observed 
in patients treated according to PEF measurements and symptoms only (Sont et al. 1999). 
Even a reduction in the thickness of the subepithelial reticular layer was evident in 
bronchial biopsy specimens of patients whose treatment was guided by BHR 
measurements (Sont et al. 1999). 
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9.2.4 Association between FENO, BHR, and EIB only in atopics 
Our study showed a significant association between FENO and severity of EIB in the 
atopic group only. To the best of our knowledge, no previous reports are available 
comparing the association between FENO and bronchial responsiveness to exercise 
between atopic and nonatopic patients. The results of our study are in accordance with the 
findings of Scollo and colleagues (2000), who reported a significant association between 
baseline FENO and EIB in asthmatic children, most of whom were atopic. Our study found 
no association between FENO and EIB in the nonatopic group. El Halawani and 
colleagues (2003) demonstrated the role of FENO as a predictor of exercise-induced 
bronchoconstriction in subjects with suspected diagnosis of EIB with no history of allergic 
rhinitis or eczema. In their study, however, atopic status was not verified by objective tests. 
Measurement of FENO can possibly be of use to screen for EIB testing and therefore 
optimise the resources for exercise testing in paediatric asthma monitoring (Buchwald et 
al. 2005).
We also found EIB to be slightly but significantly more pronounced in atopic than in 
nonatopic patients despite similar reactivity in these groups in histamine challenge. The 
presence of atopy seems to facilitate the development of exercise-induced airway 
hyperresponsiveness. In a group of mainly atopic asthmatics, Koh and colleagues (2002) 
reported a significant correlation between atopy score and severity of EIB, which 
correlated with markers of eosinophilic airway inflammation in sputum and blood. Atopic 
patients have been more reactive also to AMP than are nonatopic patients (Ludviksdottir et 
al. 2000). FENO, blood eosinophils, and responsiveness to AMP correlate with eosinophils 
in bronchial biopsies from atopic asthmatics (van der Thoorn et al. 2000), suggesting that 
both level of FENO and response to AMP challenge depend on the degree of allergic 
airway inflammation.
The findings of this study indicate that concentration of exhaled nitric oxide correlates 
significantly with bronchial hyperresponsiveness, assessed either directly (histamine) or 
indirectly (exercise), in atopic but not in nonatopic young male patients with asthmatic 
symptoms. The findings also indicate that EIB correlates with level of histamine-induced 
bronchoconstriction in atopics but not in nonatopics. Whether these results in part depend 
on differences in the inflammatory profile or cytokine production, or depend on possible 
differences in duration of the inflammatory process between atopic and nonatopic patients, 
demands further study.
9.2.5 Equally elevated concentrations of exhaled nitric oxide in nonatopic 
and low-sensitised atopic asthmatics  
Higher levels of FENO appeared in our nonatopic asthmatics than in healthy controls. The 
elevated FENO in 57% of our nonatopic asthmatics is consistent with earlier findings on 
the association of FENO level with asthma, irrespective of atopy (Malmberg et al. 2005), 
and with a decrease in FENO in nonatopic asthmatics after treatment with inhaled steroids 
(Dal Negro et al. 2003). In contrast, Ludviksdottir and colleagues (1999) found similar 
FENO levels in nonatopic and atopic asthma, but the majority of their patients were on 
inhaled steroids. In contrast with our results, FENO levels have been similar in steroid-
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naive nonatopic asthma, nonatopic rhinitis, and in nonatopic healthy subjects, which can in 
part explain the very stable or mild asthma during that study (Gratziou et al. 1999).
Our study confirms earlier findings that the FENO level is higher in atopic asthma than in 
nonatopic asthma (Olin et al. 2004). The mechanisms for this are still obscure. The similar 
FENO in nonatopic and low-sensitised atopic asthma probably reflects a similar low level 
of eosinophilic airway inflammationbetween them, even though their levels of blood 
eosinophils are not similar, whereas the high eosinophilic bronchial inflammation may be 
more marked in the high-sensitised group (Amin et al. 2000 and Rytilä 2002). 
Linear regression analysis showed, moreover, that in atopic asthmatic patients, the 
severity of EIB and number of blood eosinophils, and also sensitisation to cats were the 
most important determinants of FENO. Our results are consistent with those of Olin and 
colleagues (2004) showing that being sensitised to perennial allergens in asthma raised 
the level of FENO compared to asthmatic patients’ sensitisation to seasonal allergens and 
to that of nonatopic asthmatics. Moreover, atopic subjects sensitised only to house dust 
mite (HDM), independently of having asthma or not, had an increased level of FENO 
(Barreto et al. 2001).  Furthermore, levels of FENO have been significantly higher in 
patients with asthma who were both sensitised and exposed to relevant allergens than in 
those who were sensitised but not exposed. FENO may thus be a marker of the airway 
inflammation induced by domestic exposure to allergens in sensitised asthmatics 
(Simpson et al. 1999). Sensitisation to perennial allergens (e.g., cat and HDM) has also 
led to increased levels of FENO in asthma (Langley et al. 2003). In atopic children, 
elevated FENO was associated with sensitisation to perennial allergens, but not to 
seasonal allergens such as grass pollen. Furthermore, an increase in FENO was 
associated with BHR and current wheezing, suggesting that FENO was more than just a 
marker for atopy (Leuppi et al. 2002). In Finland HDM is not a major allergen because of 
central heating and dry indoor air; cats produce the most important perennial allergen, 
especially for younger adults (Pallasaho et al. 2006). 
To the best of our knowledge, this is the first study showing that steroid-naive nonatopic 
asthmatics and low-sensitised atopic asthmatics have equal levels of FENO as well as 
BHR both to histamine and to exercise. Similar exposure to relevant allergens during 
military service (the same kind of accommodations, no animal exposure) may contribute. 
All study subjects had asthmatic symptoms during the previous month, which in atopic 
patients was associated with FENO in one population study (Olin et al. 2006). In atopic 
patients, sensitisation to cats was strongly associated with FENO.
Our finding that the level of BHR to histamine and exercise is lower in nonatopic asthma 
than in high-sensitised atopic asthma is consistent with previous findings (Obase et al. 
1999). Furthermore, asthmatics sensitised and then exposed to high levels of sensitizing 
allergens had lower baseline FEV1 and more severe BHR than did asthmatics not 
sensitised and exposed to relevant allergens (Langley et al. 2003). Schwartz and 
colleagues (2002) showed in a population study that BHR to methacholine increased with 
number of positive skin-prick tests. In one retrospective study in asthmatics, skin prick 
reactivity to aeroallergens was also associated with BHR to methacholine (Fowler et al. 
2003). In our study, the degree of atopy was significant where BHR to an indirect stimulus 
was concerned: The magnitude of EIB was higher in high-sensitised atopic asthmatics 
than in nonatopic asthmatics. Similarly, the reactivity to AMP has been higher in atopic 
than in nonatopic asthmatics (Ludviksdottir et al. 2000). Differences in BHR between these 
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groups may be explained by the recent finding that accumulation of  mast cells in the 
smooth muscle compartment is more prominent in atopic than in nonatopic asthma (Amin 
et al. 2005). 
Our study indicates that FENO is equally elevated in nonatopic asthma and in low-
sensitised atopic asthma but is lower than in high-sensitised atopic asthma among young 
adult conscripts. These differences in FENO between the asthma groups parallel the 
differences in airway function disturbance in terms of responsiveness to histamine or 
exercise in steroid-naive non-smoking young men. 
9.3 Clinical implications 
Asthma has been traditionally diagnosed with lung function and PEF follow-up. These 
conventional measurements can only detect the functional disturbance of asthma. Based 
upon recent knowledge of the pathophysiology of asthma, the functional disturbance was 
the end result of inflammation processes. Inflammation in the airways can be measured by 
exhaled nitric oxide measurements; the level of FENO is directly associated with the 
degree of airway inflammation, particularly eosinophils. The present study showed that 
patients with respiratory symptoms who did not fulfil the diagnostic criteria of asthma had 
FENO values significantly higher than in healthy subjects but significantly lower than in 
asthma patients. This is in line with other studies in such patients, showing that elevated 
levels of FENO have been found in both the bronchial and alveolar components of FENO, 
and the alveolar component of FENO correlated with blood eosinophils and urinary 
leukotriene E4 (Lehtimäki 2003). Furthermore, sputum eosinophils have been increased in 
patients with symptoms suggesting asthma but with normal lung function and with their 
level of sputum eosinophils lower than in asthma (Rytilä et al. 2000). When these patients 
were followed up for 1 year, 13% of patients developed asthma during the follow-up. 
Similarly, among children with asthmatic symptoms but normal lung function, 33% 
developed asthma during a 2-year follow-up (Remes et al. 1998). The present and other 
studies have demonstrated the important of early detection of bronchial inflammation 
before lung function disturbance caused by remodelling of asthma. 
The level of FENO was associated with bronchial hyperresponsiveness measured by a 
direct method (histamine challenge) or an indirect method (exercise challenge) in steroid-
naive symptomatic, non-smoking asthmatics. Although these associations can be found 
only in atopics, the level of FENO is also increased in nonatopic asthma. These findings 
demonstrate that FENO can be used in the diagnosis of asthma in both atopic and 
nonatopic patients with asthma; moreover, knowledge of the atopic status of each patient 
is relevant, before measurement of FENO. 
The present study demonstrated that measurement of FENO had good reproducibility, and 
the variability of FENO was reasonable in the short- and long-term in both healthy subjects 
and patients with respiratory symptoms or asthma. We demonstrated the upper normal 
limit for healthy subjects, which was 12 ppb calculated from two different study populations 
(II, V). From our experience, this level was the best for distinguishing between healthy 
subjects and patients with asthmatic symptoms or asthma. Based on our results, the limit 
for a significant change after 6 hours and 24 hours was also calculated for possible future 
intervention studies. 
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In short, measurement of FENO is easy to perform and is a noninvasive method to assess 
inflammation in the airways. The present series of investigations thus has several 
important clinical indications. 
These findings (Study III) suggest that BHR to histamine is a sensitive indicator of the 
effect of ICS and a valuable tool for adjustment of corticosteroid treatment in mild asthma. 
The positive correlation found between the within-subject changes in PD15FEV1 and the 
peak FENO suggests that both methods can serve in evaluation of treatment with ICS in 
asthma. The findings further suggest that intermittent treatment periods of a few weeks’ 
duration are insufficient to provide long-term control of BHR in patients with mild persistent 
asthma. Furthermore, the results of the present study suggest that use of inhaled 
corticosteroids should be stopped 4 weeks before a diagnostic procedure for BHR to 
histamine.
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10 Conclusions
1. FENO was not related to age or sex in healthy subjects. We found no significant 
long-term variability in FENO. These results suggest that FENO measurement can 
be reproducible. We found that FENO levels in healthy subjects were less than 12 
ppb.
2. Patients with suspected asthma who did not fulfil the diagnostic criteria of asthma 
had FENO values significantly higher than in healthy subjects, but significantly 
lower than asthma patients. Measurement of exhaled nitric oxide by using a 
standardised method based on ERS guidelines was well reproducible over a short 
period in the short term in healthy subjects, in patients with suspected asthma, and 
in mild asthma. 
3. A daily dose of 500 μg FP significantly reduced BHR to histamine by inducing a 
sustained effect within 3 days and a maximal effect within 6 weeks after the start of 
treatment in patients with mild asthma. After cessation of FP treatment, BHR seems 
to return to near pretreatment levels within 2 weeks. These findings suggest that 
BHR to histamine may be a sensitive indicator of the effect of ICS and a valuable 
tool for adjustment of corticosteroid treatment in mild asthma. The findings further 
suggest that intermittent treatment periods of a few weeks’ duration are insufficient 
to provide long-term control of BHR in patients with mild, persistent asthma. 
4. FENO was associated with bronchial hyperresponsiveness measured by a direct 
method (histamine challenge) or an indirect method (exercise challenge) only in 
atopics when steroid-naive symptomatic, non-smoking asthmatics were studied. 
These associations were non-significant in nonatopics. 
5. FENO was equally elevated in nonatopic asthma and in low-sensitised atopic 
asthma but was lower than in high-sensitised atopic asthma among young adult 
conscripts. These differences in FENO between the asthma groups parallel the 
differences in airway function disturbance in terms of responsiveness to histamine 
or exercise in steroid-naive non-smoking young men. 
6161
11 Acknowledgements 
This study was carried out at the Laboratory of Clinical Physiology, Laboratory 
Department, Helsinki University Central Hospital. 
I am deeply grateful to my supervisor Professor Anssi Sovijärvi for all his guidance and 
support during the years. I am most grateful for his patient guidance in scientific writing in 
English and especially in logical and precise expression in scientific writing. 
I would like to thank Professor Lauri A. Laitinen, former Chief Executive Officer of the 
Helsinki and Uusimaa Hospital Federation, for providing me the opportunity to engage in 
clinical research and for providing me with the facilities needed. He also helped me in 
guidance on practical matters of the dissertation and in finalizing the thesis. 
I am most grateful to the reviewers of the thesis, Docents Kirsi Timonen and Seppo 
Saarelainen for the constructive review of this thesis. 
I am deeply grateful to my colleague and co-author Annamari Rouhos, MD, for her 
excellent comments and support during this process. I wish to thank Docent Jouko 
Karjalainen for sharing his expertise in asthma and especially in exercise-induced asthma. 
Without his support and valuable comments this thesis would never have been finished. 
I warmly thank Professor Tari Haahtela, Docent Ari Lindqvist, Docent Juha Tuominen, 
Paula Pallasaho, PhD, and Dr Antti Saarinen for their collaboration and co-authorship. I 
am deeply grateful to Professor Seppo Sarna and to Tuija Poussa for sharing their 
expertise in statistical problems. 
I wish to thank the staff of the Laboratory of Clinical Physiology for excellent 
measurements of FENO, and the staff of the Central Military Hospital for excellent 
assistance in patient recruiting and in performance of exercise challenges even in 
wintertime, and the staff of the Research Unit of Pulmonary Diseases for excellent 
measurements of BHR and for the lovely spirit which filled their unit. 
I express my gratitude to Sirkku Vilkman, PhD, for arranging time from clinical duties at 
Porvoo Hospital for my research work. 
I thank all of my colleagues (Adel, Aija, Annette, Harri, Heidi, Henrik, Hilkka, Hille, Irmeli, 
Juho, Laura, Maija, Milla, Paula K, Paula M, Paula R, Pentti, Ulla, and many others) at the 
Helsinki University Central Hospital, Division of Pulmonary Medicine. 
I am grateful to all patients and controls who volunteered to participate in these studies 
and made them possible. 
Finally, I would like to thank my family for their support. I thank my beloved wife, Pirkko, 
especially for her technical aid with various computer software. I also thank our daughters, 
Petra-Maria and Erica, for help in releasing my mind from scientific work and for all the 
games we played together. 
6262
Friendly thanks to Carol Norris for some language aid. 
This study was supported by grants from the Allergy Research Foundation, the Finnish 
Anti-Tuberculosis Foundation, the Ida Montin Foundation, the Foundation of Helsinki 
University Central Hospital, Nummela Sanatoriums Stiftelse, and the Finnish Society for 
Allergology and Immunology. 
6363
12 References
al-Ali MK Eames C Howarth PH. Exhaled nitric oxide; relationship to clinicophysiological 
markers of asthma severity. Respir Med 1998; 92:908-13. 
Alving K, Weitzberg E, Lundberg JM. Increased amount of nitric oxide in exhaled air of 
asthmatics. Eur Respir J 1993; 6:1268-1270. 
American Thoracic Society. Lung Function Testing: Selection of Reference Values and 
Interpretative Strategies. Am Rev Respir Dis 1991; 144: 1202–1218. 
American Thoracic Society. Recommendations for standardised procedures for the online 
and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide in 
adults and children - 1999. Am J Respir Crit Care Med 1999;160: 2104-2117. 
American Thoracic Society. Guidelines for Methacholine and Exercise Challenge Testing -
1999. Am J Respir Crit Care Med 2000; 161: 309-329. 
American Thoracic Society. ATS / ERS Recommendations for standardised procedures for 
the online and offline measurement of exhaled lower respiratory nitric oxide and nasal 
nitric oxide - 2005. Am J Respir Crit Care Med 2005;171: 912-930. 
Amin K, Ludviksdottir D, Janson C, Nettelbladt O, Björnsson E, Roomans GM, Boman G, 
Sevéus L, Venge P. Inflammation and structural changes in the airways of patients with 
atopic and nonatopic asthma. Am J Respir Crit Care Med 2000; 162: 2295-2301. 
Amin K, Janson C, Boman G, Venge P. The extracellular deposition of mast cell products 
is increased in hypertrophic airways smooth muscles in allergic asthma but not in 
nonallergic asthma. Allergy 2005;60:1241-7. 
Anderson SD, Connolly NM, Godfrey S. Comparison of bronchoconstriction induced by 
cycling and running. Thorax 1971; 26: 396-401. 
Anderson SD, Daviskas E. Pathophysiology of exercise-induced asthma: the role of 
respiratory water loss. In: Weiler JM, editor. Allergic and respiratory disease in sports 
medicine. New York (NY): Marcel Dekker Inc., 1997: 87-114
Aziz I, Wilson AM, Lipworth BJ. Effects of once-daily formoterol and budesonide given 
alone or in combination on surrogate inflammatory markers in asthmatic adults. Chest 
2000;118:1049-1058.
Barben J, Roberts M, Chew N, Carlin JB, Robertson CF. Repeatability of bronchial 
responsiveness to mannitol dry powder in children with asthma. Pediatr Pulmonol
2003;36:490-494.
Barnes PJ. Cytokines as mediators for chronic asthma. Am J Respir Crit Care Med 
1994;150:S42-S49.
6464
Barnes PJ and Liew FY. Nitric oxide and asthmatic inflammation. Immunol Today 1995 
;16:128-30.
Barnes PJ, Kharitonov SA. Exhaled nitric oxide: a new lung function test. Thorax 1996;51:
233-237.
Barnes PJ. Nitric oxide. In: Barnes, Rodger and Thompson, editors. Asthma: Basic 
mechanisms and Clinical Management, pp. 369-388. Academic Press, Cambridge. 
Barreto M, Villa MP, Martella S, Ronchetti F, Darder MT, Falasca C, Pagani J, Massa F, 
Ronchetti R. Exhaled nitric oxide in asthmatic and non-asthmatic children: influence of 
type of allergen sensitisation and exposure to tobacco smoke. Pediatr Allergy Immunol. 
2001;12:247-56.
Belvisi M, Barnes PJ, Larkin S, Yacoub M, Tadjkarimi S, Williams TJ, Mitchell JA. Nitric 
oxide synthase activity is elevated in inflammatory lung disease in humans. Eur J 
Pharmacol 1995; 283:255-58. 
Berkman N, Avital A, Bardach E, Springer C, Breuer R, Godfrey S. The effect of 
montelukast on bronchial provocation tests and exhaled nitric oxide levels in asthmatic 
patients. Isr Med Assoc J 2003; 5:778-81. 
Berkman N, Avital A, Breuer R, Bardach E, Springer C, Godfrey S. Exhaled nitric oxide in 
the diagnosis of asthma: comparison with bronchial provocation tests. Thorax 
2005;60(5):383-388
Bohadana A, Michaely JP, Teculescu D, Wild P. Reproducibility of exhaled nitric oxide in 
smokers and non-smokers: relevance for longitudinal studies. BMC Pulm Med. 
2008;28;8:4.
Boulet LP, Turcotte H, Laviolette M, Naud F, MC Bernier, Martel S, Chakir J. Airway 
hyperresponsiveness, inflammation, and subepithelial collagen deposition in recently 
diagnosed versus longstanding asthma. Influence of inhaled steroids. Am J Respir Crit 
Care Med 2000;162:1308-13. 
Bousquet J, Chanez P, Lacoste JY, Barneon G, Ghavanian N, Enander I, Venge P, 
Ahlstedt S, Simony-Lafontaine J, Gorard P, Michel FB. Eosinophilic inflammation in 
asthma. N Engl J Med 1990;323:1033-1039. 
Bousquet J, Chanez P, Lacoste JY, Enander I, Venge P, Peterson C, Ahlstedt S, Gorard 
P, Michel FB. Indrect evidence of bronchial inflammation assesses by titration of 
inflammatory mediators in BAL fluid of patients with asthma. J Allergy Clin Immunol 
1991;88:649-660.
Bousquet J, Vignola AM, Chanez P, Campbell AM, Bosignore G, Michel FB. Airays 
remodelling in asthma: no doubt, no more. Int Arch Allergy Immunol 1995;107:211-214. 
Brannan JD, Koskela H, Anderson SD, Chew N. Responsiveness to mannitol in asthmatic 
subjects with exercise and hyperventilation-induced asthma. Am J Respir Crit Care Med 
1998;158:1120–1126.
6565
Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID. Mast-cell 
infiltration of airway smooth muscle in asthma. N Engl J Med 2002;346:1699-1705. 
bronchoconstriction in asthmatic children. 
Buchvald F, Hermansen MN, Nielsen KG, Bisgaard H. Exhaled nitric oxide predicts 
exercise-induced bronchoconstriction in asthmatic school children. Chest 2005 ;128:1964-
1967.
Busia A, Besozzi A, Fumagalli A, Librenti MC, Robuschi M, Bianco S. Levels of nitric oxide 
exhaled air are reduced in hyberobese patients. Am J Respir Crit Care Med 1999; 
159:A860.
Carra S, Gagliardi L, Zanconato S, Scollo M, Azzolin N, Zacchello F, Baraldi E. 
Budesonide but not nedocromil sodium reduces exhaled nitric oxide levels in asthmatic 
children. Respir Med. 2001;95:734-9. 
Carroll MP,Gratzion C, Holgate ST. Inflammation and inflammatory mediators in asthma. 
In: Asthma (3rd ed.) T.J. H. Clark, S. Godfrey, and T. H. Lee, (eds.), Chapman & Hall, 
London, 1992; 182-231. 
Chang TL, Shea CH, Urioste S, Thompson RC, Boom WH, Abbas AK. Heterogeneity of 
helper / inducer T lymphocytes: lymphokine production and lymphokine responsiveness. J 
Immunol 1990; 145:2803-2808. 
Chatkin JM, Ansarin K, Silkoff PE, McClean P, Gutierrez C, Zamel N, Chapman KR. 
Exhaled nitric oxide as a noninvasive assessment of chronic cough. Am J Respir Crit Care 
Med 1999; 159: 1810-1813 
Cockroft CW. Determination of histamine PC20; comparison of linear and logaritric 
interpolation. Chest 1983;84:505-506. 
Colon-Semidey AJ, Marshik P, Crowley M, Katz R, Kelly HW. Correlation between 
reversibility of airway obstruction and exhaled nitric oxide levels in children with stable 
bronchial asthma. Pediatr Pulmonol 2000; 30:385-92. 
Convery RP, Leitch DN, Bromly C, Ward RJ, Bartlett G, Hendrick DJ. Effect of inhaled 
fluticasone propionate on airway responsiveness in treatment-naive individuals: a lesser 
benefit in females. Eur Respir J 2000;15:19–24. 
Corrigan CJ. Hamid Q. North J. Barkans J. Moqbel R. Durham S. Gemou-Engesaeth V. 
Kay AB. Peripheral blood CD4 but not CD8 t-lymphocytes in patients with exacerbation of 
asthma transcribe and translate messenger RNA encoding cytokines which prolong 
eosinophil survival in the context of a Th2-type pattern: effect of glucocorticoid therapy.
American Journal of Respiratory Cell & Molecular Biology 1995;12(5):567-78. 
Corrigan CJ. Kay AB. Asthma. Role of T-lymphocytes and lymphokines. British Medical 
Bulletin 1992 48(1):72-84. 
6666
Cotes J E, Chinn D J, Quanjer P H, Roca J, Yearnault J-C. Standardisation of the 
measurement of transfer factor (diffusing capacity). Eur Respir J 1993; 6: 41-52. 
Covar RA, Szefler SJ, Martin RJ, Sundstrom DA, Silkoff PE, Murphy J, Young DA, Spahn 
JD. Relations between exhaled nitric oxide and measures of disease activity among 
children with mild-to-moderate asthma. J Pediatr 2003; 142:469-75. 
Currie GP, Bates CE, Lee DK, Carey FA, Lipworth BJ. Effects of fluticasone plus 
salmeterol versus twice the dose of fluticasone in asthmatic patients. Eur J Clin Pharmacol 
2003; 59:11-5. 
Dal Negro R, Micheletto C, Tognella S, Turco P, Rossetti A, Cantini L. Assessment of 
inhaled BDP-dose dependency of exhaled nitric oxide and local and serum eosinophilic 
markers in steroid-naïve nonatopic asthmatics. Allergy 2003;58:1018-1022. 
de Gouw HWFM, Grunberg K, Schot R, Kroes AC, Dick EC, Sterk PJ. Relationship 
between exhaled nitric oxide and airway hyperresponsiveness following experimental 
rhinovirus infection in asthmatic subjects. Eur Respir J  1998;11: 126-132. 
de Kluijver J, Evertse CE, Schrumpf JA, van der Veen H, Zwinderman AH, Hiemstra PS,
Rabe KF, Sterk PJ. Asymptomatic Worsening of Airway Inflammation during Low-Dose 
Allergen Exposure in Asthma: Protection by Inhaled Steroids. Am J Respir Crit Care Med 
2002; 166(3): 294 - 300. 
Delgado-Corcoran C, Kissoon N, Murphy SP, Duckworth LJ  Exhaled nitric oxide reflects 
asthma severity and asthma control.  Pediatr Crit Care Med 2004; 5:48-52. 
Denham S, Koppelman GH, Blakey J, Wjst M, Ferreira MA, Hall IP, Sayers I. Meta-
analysis of genome-wide linkage studies of asthma and related traits. Respir Res 
2008;9:38.
Deykin A, Halpern O, Massaro AF, Drazen JM, Israel E. Expired nitric oxide after 
bronchoprovocation and repeated spirometry in patients with asthma. Am J Respir Crit 
Care Med 1998;157:769-75. 
Deykin A, Massaro AF, Coulston E, Drazen JM, Israel E. Exhaled NO following repeated 
spirometry or repeated plethysmography in healthy individuals. Am J Respir Crit Care Med 
2000; 161: 1237-1240.  
Deykin A, Massaro AF, Drazen JM, Israel E . Exhaled nitric oxide as a diagnostic test for 
asthma: online versus offline techniques and effect of flow rate. Am J Respir Crit Care Med 
2002; 165 :1597-601. 
Djukanovi? R, Wilson JW, Britten KM, Wilson SJ, Walls AF, Roche WR, Howarth PH, 
Holgate ST. Quantitation of mast cells and eosinophils in the bronchial mucosa of 
symptomatic atopic asthmatics and healthy control subjects using immunohistochemistry.
Am Rev Respir Dis 1990; 142 :863-71. 
Dunnill MS. The pathology of asthma, with special reference to changes in the bronchial 
mucosa. J Clin Pathol 1960;13:27–33. 
6767
Dunnill MS, Massarella GR, Anderson JA. A comparison of the quantitative anatomy of the 
bronchi in normal subjects, in status asthmaticus, in chronic bronchitis, and in 
emphysema. Thorax 1969;24:176-9. 
Dupont LJ Rochette F Demedts MG, Verleden GM. Exhaled nitric oxide correlates with 
airway hyperresponsiveness in steroid-naive patients with mild asthma. Am J Respir Crit 
Care Med 1998; 157:894-8. 
Dupont LJ, Demedts MG, Verleden GM. Prospective evaluation of the validity of exhaled 
nitric oxide for the diagnosis of asthma. Chest 2003; 123:751-6. 
El Halawani SM, Ly NT, Mahon RT, Amundson DE. Exhaled nitric oxide as a predictor of 
exercise-induced bronchoconstriction. Chest 2003; 124: 639-643. 
European Respiratory Society. Eur Respir J 1993;6 (Suppl): 41-52. 
Fahy JV, Kim KW, Liu J, Boushey HA. Respiratory pathophysiology responses – 
prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. J 
Allergy Clin Immunol 1995;95:843-852. 
Fowler SJ, Lipworth BJ. Relationship of skin-prick reactivity to aeroallergens and 
hyperresponsiveness to challenges with methacholine and adenosine monophosphate. 
Allergy 2003; 58:46-52. 
Franklin PJ, Taplin R, Stick SM. A community study of exhaled nitric oxide in healthy 
children. Am J Respir Crit Care Med 1999;159:69-73. 
Franklin PJ, Turner SW, Le Souëf PN, Stick SM. Exhaled nitric oxide and asthma: complex 
interactions between atopy, airway responsiveness, and symptoms in a community 
population of children. Thorax  2003;58:1048-52. 
Franklin PJ, Stick SM, Le Souëf PN, Ayres JG, Turner SW. Measuring exhaled nitric oxide 
levels in adults: the importance of atopy and airway responsiveness. Chest  
2004;126:1540-5.
Gabbay E, Fischer AJ, Small T, Leonard AJ, Corris PA. Exhaled single-breath nitric oxide 
measurements are reproducible, repeatable and reflect levels of nitric oxide found in the 
lower airways. Eur Respir J 1998;11:467-472.
Gauvreau GM, Ronnen GM,Watson RM, O’Byrne PM. Exercise-induced 
bronchoconstriction does not cause eosinophilic airway inflammation or airway 
hyperresponsiveness in subjects with asthma. Am J Respir Crit Care Med 2000;162: 1302-
1307.
Gershman NH, Wong HH, Liu JT, Fahy JV. Low- and high-dose fluticasone propionate in 
asthma; effects during and after treatment. Eur Respir J 2000;15:11–8. 
6868
Ghiro L, Zanconato S, Rampon O, Piovan V, Pasquale MF, Baraldi E. Effect of 
montelukast added to inhaled corticosteroids on fractional exhaled nitric oxide in asthmatic 
children. Eur Respir J. 2002;20:630-4. 
Gibson PG, Allen CJ, Yang JP, Wong BJ, Dolovich J, Denburg J, Hargreave FE. 
Intraepithelial mast cells in allergic and nonallergic asthma. Assessment using bronchial 
brushings. Am Rev Respir Dis 1993;148:80-6. 
Gibson PG, Saltos N, Fakes K. Acute anti-inflammatory effects of inhaled budesonide in 
asthma: a randomised controlled trial. Am J Respir Crit Care Med 2001;163:32–6. 
Gilbert JA, Misner JE. Failure to find increased TEM at rest and during exercise in 
aerobically trained and resistance trained subjects. Int J Sport Nutr 1993;3:55-66. 
Global Strategy for Asthma Management and Prevention (GINA 2007). 
http://www.ginasthma.org.
Gotshall RW. Drugs 2002; 62:1725-1739. 
Gratziou CH, Lignos M, Dassiou M. Influence of atopy on exhaled NO in patients with 
stable asthma and rhinitis. Eur Respir J 1999; 14: 897-901. 
Gratziou C, Rovina N, Lignos M, Vogiatzis I, Roussos C. Exhaled nitric oxide in seasonal 
allergic rhinitis: influence of pollen season and therapy. Clin Exp Allergy. 2001;31:409-16. 
Gustafsson LE, Leone AM, Persson MG, Wiklund NP, Moncada S. Endogenous nitric 
oxide is present in the exhaled air of rabbits, guinea pigs and humans. Biochem Biophys 
Res Commun. 1991;181:852-7. 
Haley KJ, Sunday ME, Wiggs BR, Kozakewich HP, Reilly JJ, Mentzer SJ., Sugarbaker 
MD, Doersckuk CM, Drazen JM. Inflammatory cell distribution within and along asthmatic 
airways. Am J Respir Crit Care Med 1998;158:565-572.
Hamid Q, Springall DR, Riveros-Moreno V, Chanez P, Howarth P, Redington A, Bousquet 
J, Godard P, Holgate S, Polak JM. Induction of nitric oxide synthase in asthma. Lancet
1993;342:1510-1513.
Harkins MS, Fiato KL, Iwamoto GK. Exhaled nitric oxide predicts asthma exacerbation. J 
Asthma 2004; 41 :471-6. 
Ho LP, Wood FT, Robson A, Innes JA, Greening AP. Atopy influences exhaled nitric oxide 
levels in adult asthmatics. Chest 2000; 118: 1327-1331. 
Hofstra WB, Neijens HJ, Duiverman EJ, Kouwenberg JM, Mulder PG, Kuethe MC, Sterk 
PJ. Dose-responses over time to inhaled fluticasone propionate treatment of exercise- and 
methacholine-induced bronchoconstriction in children with asthma. Pediatr Pulmonol. 
2000;29: 415-423. 
6969
Högman M, Strömberg S, Schedin U, Frostell C, Hedenstierna G, Gustafsson LE. Nitric 
oxide from the human respiratory tract efficiently quantified by standardised single breath 
measurements. Acta Physiol Scand 1997;159: 345-346. 
Högman M, Holmkvist T, Wålinder R, Meriläinen P, Lúdvíksdóttir D, Håkansson L, 
Hedenström H. Increased nitric oxide elimination from the airways after smoking 
cessation. Clin Sci  2002;103:15-9. 
Horvath I, Barnes PJ. Exhaled monoxides in asymptomatic atopic subjects. Clin Exp 
Allergy 1999; 29: 1276-1280.
Howell JBL. Asthma: clinical descriptions and definions. In: Busse WW, Holgate ST, 
editors. Asthma and rhinitis. 1st ed. Boston:Blackwell Scientific; 1995:3-5. 
Huber HL, Koessler KK. The pathology of bronchial asthma. Arch Intern Med 
1922;30:689–760.
Hung CH, Lee MY, Tsai YG, Cheng SN, Yang KD. Hyposensitisation therapy reduced 
exhaled nitric oxide in asthmatic children with corticosteroid dependency. Acta Paediatr 
Taiwan. 2004;45:89-93. 
International consensus report on diagnosis and treatment of asthma. National Heart, 
Lung, and Blood Institute, National Institutes of Health. Eur  Respir  J 1992; 5:601-641. 
Jarjour NN, Peters P, Djukanovic R, Calhoun WJ. Investigate use of bronchoscopy in 
asthma. Am J Respir Crit Care Med 1998;157:692-697. 
Jatakanon A, Lim S, Kharitonov SA, Chung KF, Barnes PJ. Correlation between exhaled 
nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild 
asthma. Thorax 1998;53:91-95.
Jatakanon A, Uasuf CG, Maziak W, Lim S, Chung KF, Barnes PJ. Neutrophilic 
inflammation in severe persistent asthma. Am J Respir Crit Care Med 1999; 160: 1532-
1539.
Jatakanon A, Kharitonov SA, Lim S, Barnes PJ. Effect of differing doses of inhaled 
budesonide on markers of airway inflammation in patients with mild asthma. Thorax 1999; 
54: 108-114. 
Jeffery P. Bronchial biopsies and airway inflammation. Eur Respir J 1996;9:1583-1587. 
Jeffery PK, Wardlaw AJ, Nelson FC, Collins JV, Kay AB. Bronchial biopsies in asthma: an 
ultrastructural, quantitative study and correlation with hyperreactivity. Am Rev Respir Dis 
1989;140:1745-1753.
Johansson SG, Hourihane JO, Bousquet J, Bruijnzeel-Koomen C, Dreborg S, Haahtela T, 
Kowalski ML, Mygind N, Ring J, van Cauwenberge P, van Hage-Hamsten M, Wüthrich B; 
EAACI (the European Academy of Allergology and Cinical Immunology) nomenclature task 
force. A revised nomenclature for allergy. An EAACI position statement from the EAACI 
nomenclature task force. Allergy 2001; 56:813-24. 
7070
Jones SL, Kittelson J, Cowan JO, Flannery EM, Hancox RJ, McLachlan CR, Taylor DR. 
The predictive value of exhaled nitric oxide measurements in assessing changes in 
asthma control.  Am J Respir Crit Care Med 2001; 164:738-43. 
Juniper EF, Kline PA, Vanzieleghem MA, Ramsdale EH, O'Byrne PM, Hargreave FE. 
Long-term effects of budesonide on airway responsiveness and clinical asthma severity in 
inhaled steroid-dependent asthmatics. Eur Respir J 1990;3:1122-7. 
Kanniess F, Richter K, Bohme S, Jorres RA, Magnussen H. Montelukast versus 
fluticasone: effects on lung function, airway responsiveness and inflammation in moderate 
asthma. Eur Respir J. 2002;20(4):853-8. 
Karjalainen J, Lindqvist A, Laitinen LA. Seasonal variability of exercise-induced asthma 
especially outdoors. Effect of birch pollen allergy. Clin Exp Allergy 1989; 19:273-8. 
Karjalainen J. Exercise response in 404 young men with asthma: no evidence for a late 
asthmatic reaction. Thorax 1991; 46: 100-104. 
Keatings VM, Barnes PJ. Granulocyte activation markers in induced sputum: Comparison 
between chronic obstructive pulmonary disease, asthma and normal subjects. Am J Respir 
Crit Care Med 1997;155:449-453. 
Kelley J. Cytokines of the lung. Am Rev Respir Dis 1990;141:765-788. 
Khalili B, Boggs PB, Bahna SL. Reliability of a new hand-held device for the measurement 
of exhaled nitric oxide. Allergy 2007;6210):1171-4. 
Kharitonov SA, Yates D, Robbins RA, Logan-Sinclair R, Shinebourne EA, Barnes PJ. 
Increased nitric oxide in exhaled air of asthmatic patients. Lancet 1994;343:133-135.
Kharitonov SA, Robbins RA, Yates DH, Keatings V, Barnes PJ. Acute and chronic effects 
of cigarette smoking on exhaled nitric oxide. Am J Respir Crit Care Med 1995; 152: 609-
612.
Kharitonov SA, O'Connor BJ, Evans DJ, Barnes PJ. Allergen-induced late asthmatic 
reactions are associated with elevation of exhaled nitric oxide. Am J Respir Crit Care Med 
1995; 151: 1894-1899. 
Kharitonov SA, Yates DH, Barnes PJ. Inhaled glucocorticoids decrease nitric oxide in 
exhaled air of asthmatic patients. Am J Respir Crit Care Med 1996;153:454-457.
Kharitonov SA, Alving K, Barnes PJ. Exhaled and nasal nitric oxide measurements: 
recommendations. Eur Respir J 1997;10:1683-1693. 
Kharitonov SA and Barnes PJ. Exhaled markers of pulmonary disease. Am J Respir Crit 
Care Med 2001;163:1693–1722. 
7171
Kharitonov SA, Donnelly LE, Corradi M, Montuschi P, Barnes PJ. Dose-dependent onset 
and cessation of action of inhaled budesonide on exhaled nitric oxide and symptoms in 
mild asthma. Thorax 2002;57:889-96. 
Kharitonov SA, Gonio F, Kelly C, Meah S, Barnes PJ  Reproducibility of exhaled nitric 
oxide measurements in healthy and asthmatic adults and children.  Eur Respir J 2003; 
21:433-8.
Kissoon N, Duckworth LJ, Blake KV, Murphy SP, Lima JJ. Effect of beta2-agonist 
treatment and spirometry on exhaled nitric oxide in healthy children and children with 
asthma. Pediatr Pulmonol 2002; 34:203-8.
Koh YI, Choi IS, Lim S. Atopy may be related to exercise-induced bronchospasm in 
asthma. Clin Exp Allergy 2002; 32: 532-536. 
Koskela HO, Hyvärinen L, Brannan JD, Chan HK, Anderson SD. Sensitivity and validity of 
three bronchial provocation tests to demonstrate the effect of inhaled corticosteroids in 
asthma. Chest 2003;124:1341-1349. 
Koskela HO, Hyvärinen L, Brannan JD, Chan HK, Anderson SD. Responsiveness to three 
bronchial provocation tests in patients with asthma. Chest 2003;124:2171-2177. 
Kotaniemi JT, Lundback B, Nieminen MM, Sovijarvi AR, Laitinen LA. Increase of asthma in 
adults in northern Finland?--a report from the FinEsS study. Allergy 2001;56:169-74. 
Laitinen LA, Heino M, Laitinen A, Kava T, Haahtela T. Damage of the airways epithelium 
and bronchial reactivity in patients with asthma. Am Rev Respir Dis 1985; 131:599-606. 
Laitinen LA, Laitinen A, Heino M, Haahtela T. Eosinophilic airway inflammation during 
exacerbation of asthma and its treatment with inhaled corticosteroid. Am Rev Respir Dis. 
1991; 143:423-7. 
Laitinen LA, Laitinen A, Haahtela T. A comparative study of the effects of inhaled 
corticosteroid, budenoside, and a ?2-agonist, terbutaline, on airway inflammation in newly 
diagnosed asthma: a randomised, double-blind, parallel-group controlled trial. J Allergy 
Clin Immunol 1992; 90:32-42. 
Laitinen LA. Laitinen A. Haahtela T. Airway mucosal inflammation even in patients with 
newly diagnosed asthma. Am Rev Respir Dis 1993; 147:697-704. 
Lamblin C, Gosset P, Tillie-Leblond I, Saulnier F, Marquette CH, Wallaert B, Tonnel AB. 
Bronchial neutrophilia in patients with noninfectious status asthmaticus. Am J Respir Crit 
Care Med 1998; 157:394-402. 
Lane C, Knight D, Burgess S, Franklin P, Horak F, Legg J, Moeller A, Stick S  Epithelial 
inducible nitric oxide synthase activity is the major determinant of nitric oxide concentration 
in exhaled breath. Thorax 2004; 59:757-60. 
7272
Langley SJ, Goldthorpe S, Custovic A, Woodcock A. Relationship among pulmonary 
function, bronchial reactivity, and exhaled nitric oxide in a large group of asthmatic 
patients.  Ann Allergy Asthma Immunol 2003; 91:398-404. 
Latvala J, Karjalainen J, Remes J, et al. Exercise-induced asthma and weather (abstract). 
XXXIII International Congress of Military Medicine. Helsinki, Finland, 25-30 June 2000. 
Latzin P, Beck J, Griese M . Exhaled nitric oxide in healthy children: variability and a lack 
of correlation with atopy.  Pediatr Allergy Immunol 2002; 13(1) :37-46. 
Lee TH. Mediators of bronchial responsiveness. In Asthma (3rd ed.). TJH Clark, S Gofrey, 
and TH Lee (eds.), Chapman & Hall, London, 1992;162-181. 
Lee DK, Jackson CM, Currie GP, Cockburn WJ, Lipworth BJ. Comparison of combination 
inhalers vs inhaled corticosteroids alone in moderate persistent asthma. Br J Clin 
Pharmacol 2003; 56:494-500. 
Lee DK, Jackson CM, Haggart K, Lipworth BJ. Repeated dosing effects of mediator 
antagonists in inhaled corticosteroid-treated atopic asthmatic patients. Chest 2004; 125(4) 
:1372-7.
Lehtimäki L. Measurement of exhaled nitric oxide. Differentiation between alveolar and 
bronchial inflammation by using multiple exhalation flow rates. Acta Universitatis 
Tamperensis; 925, Tampereen yliopisto, Tampere 2003. 
Lehtimäki L, Kankaanranta H, Saarelainen S, Turjanmaa V and Moilanen E. Peripheral 
inflammation in patients with asthmatic symptoms but normal lung function. J Asthma 
2005; 42:605-9. 
Leuppi JD, Salome CM, Jenkins CR, Koskela H, Brannan JD, Anderson SD, Andersson M, 
Chan HK, Woolcock AJ. Markers of airway inflammation and airway hyperresponsiveness 
in patients with well-controlled asthma. Eur Respir J 2001;18:444-450. 
Leuppi JD Downs SH Downie SR et al. Exhaled nitric oxide levels in atopic children: 
relation to specific allergic sensitisation, AHR, and respiratory symptoms. Thorax 2002; 
57:518-23.
Levesque MC, Hauswirth DW, Mervin-Blake S, Fernandez CA, Patch KB, Alexander KM, 
Allgood S, McNair PD, Allen AS, Sundy JS. Determinants of exhaled nitric oxide levels in 
healthy, nonsmoking African American adults. J Allergy Clin Immunol 2008;121:396-402. 
Lim S, Jatakanon A, John M, Gilbey T, O'Connor BJ, Barnes PJ. Effect of inhaled 
budesonide on lung function and airway inflammation. Am J Respir Crit Care Med 1999; 
159: 22-30. 
Lim S, Jatakanon A, Meah S, Oates T, Chung KF, Barnes PJ. Relationship between 
exhaled nitric oxide and mucosal eosinophilic inflammation in mild to moderately severe 
asthma. Thorax 2000;55:184-8. 
7373
Lindqvist A, Karjalainen EM, Laitinen LA, Kava T, Altraja A, Pulkkinen M, Halme M, 
Laitinen A. Salmeterol resolves airway obstruction but does not possess anti-eosinophil 
efficacy in newly diagnosed asthma: a randomised, double-blind, parallel group biopsy 
study comparing the effects of salmeterol, fluticasone propionate, and disodium 
cromoglycate. J Allergy Clin Immunol 2003;112(1):23-8. 
Little SA, Chalmers GW, MacLeod KJ, McSharry C, Thomson NC. Non-invasive markers 
of airway inflammation as predictors of oral steroid responsiveness in asthma. Thorax 
2000; 55 :232-4. 
Lopuhaa CE, Koopmans JG, Jansen HM, van der Zee JS. Similar levels of nitric oxide in 
exhaled air in non-asthmatic rhinitis and asthma after bronchial allergen challenge. Allergy 
2003;58:300-5.
Ludviksdottir D, Janson C, Björnsson E, Stålenheim G, Boman G, Hedenström H, Venge 
P, Gudbjörnsson B, Valtysdóttir S. Different airway responsiveness profiles in atopic 
asthma, nonatopic asthma and Sjögren’s syndrome. Allergy  2000; 55: 259-265. 
Ludviksdottir D, Janson C, Hogman M, Hedenstrom H, Bjornsson E, Boman G. Exhaled 
nitric oxide and its relationship to airway responsiveness and atopy in asthma: BHR-Study 
Group. Respir Med 1999; 93: 552-556.
Makker HK, Montefort S, Holgate S. Investigative use of fibreoptic bronchoscopy for local 
airway challenge in asthma. Eur Respir J 1993; 6:1402-8. 
Malmberg LP, Pelkonen AS, Haahtela T, Turpeinen M. Exhaled nitric oxide rather than 
lung function distinguishes preschool children with probable asthma. Thorax 2003; 58:494-
9.
Malmberg LP, Turpeinen H, Rytila P, Sarna S, Haahtela T. Determinants of increased 
exhaled nitric oxide in patients with suspected asthma. Allergy 2005; 60:464-468. 
Mattes J, Storm van's Gravesande K, Reining U, Alving K, Ihorst G, Henschen M, and 
Kuehr J. NO in exhaled air is correlated with markers of eosinophilic airway inflammation 
in corticosteroid-dependent childhood asthma. Eur Respir J 1999;13: 1391-1395. 
Meyts I, Proesmans M, De Boeck K. Exhaled nitric oxide corresponds with office 
evaluation of asthma control. Pediatr Pulmonol 2003; 36:283-9. 
Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathology and 
pharmacology. Pharmacol Rev 1991;43:109-142. 
Moody A, Fergusson W, Wells A, Bartley J, Kolbe J. Increased nitric oxide production in 
the respiratory tract in asymptomatic Pacific Islanders: an association with skin prick 
reactivity to house dust mite. J Allergy Clin Immunol 2000; 105: 895-899. 
Morris NH, Sooranna SR, Steer PJ, Warren JB. The effect of the menstrual cycle on 
exhaled nitric oxide and urinary nitrate concentration. European J Clin Invest 1996;26,481-
484.
7474
Nathan C, Xie Q-W. Nitric oxide synthases: roles, tolls and controls. Cell 1994;78:915-918. 
Obase Y, Shimoda T, Mitsuta K, Matsuo N, Matsuse H, Kohno S. Sensitivity to the house 
dust mite and airway hyperresponsiveness in a young adult population. Ann Allergy 
Asthma Immunol 1999;83:305-310. 
O´Sullivan S, Roquet A, Dahlén B, Larsen F, Eklund A, Kumlin M, O´Byrne PM, Dahlén S-
E: Evidence for mast cell activation during exercise-induced bronchoconstriction. Eur 
Respir J 1998; 12: 345-350. 
Olin AC, Alving K, Toren K. Exhaled nitric oxide: relation to sensitisation and respiratory 
symptoms. Clin Exp Allergy 2004; 34:221-6. 
Olin AC, Rosengren A, Thelle DS, Lissner L, Bake B, Torén K. Height, age, and atopy are 
associated with fraction of exhaled nitric oxide in a large adult general population sample. 
Chest  2006; 130:1319-25. 
Olin AC, Bake B, Torén K. Fraction of exhaled nitric oxide at 50 mL/s: reference values for 
adult lifelong never-smokers. Chest 2007; 131:1852-6. 
Osler W. Diseases of the respiratory system: bronchial asthma. In: The principles and 
practice of medicine, 4th ed. New York: D. Appleton and Company; 1901. p. 628–632. 
Pallasaho P, Rönmark E, Haahtela T, Sovijärvi AR, Lundbäck B. Degree and clinical 
relevance of sensitised to common allergens among adults: a population study in Helsinki, 
Finland. Clin Exp Allergy 2006;36:503-9. 
Payne DN, Adcock IM, Wilson NM, Oates T, Scallan M, Bush A. Relationship between 
exhaled nitric oxide and mucosal eosinophilic inflammation in children with difficult asthma, 
after treatment with oral prednisolone. Am J Respir Crit Care Med 2001; 164: 1376-81. 
Persson MG, Gustafsson LE. Ethanol can inhibit nitric oxide production. Eur Respir J 
1992;224: 99-100. 
Persson MG, Zetterström O, Aargenius V, Ihre E, Gustafsson LE. Single breath oxide 
measurements in asthmatic patients and smokers. Lancet 1994;343:146-147.
Phillips CR, Giraud GD, Holden WE. Exhaled nitric oxide during exercise: site of release 
and modulation by ventilation and blood flow. J Appl Physiol 1996;80:1865-1871. 
Piacentini GL Bodini A Costella S. Exhaled nitric oxide, serum ECP and airway 
responsiveness in mild asthmatic children. Eur Respir J 2000;15:839-43. 
Piacentini GL, Bodini A, Costella S, Vicentini L, Mazzi P, Suzuki Y, Peroni D, Boner AL. 
Exhaled nitric oxide in asthmatic children exposed to relevant allergens: effect of 
flunisolide. Eur Respir J 2000; 15: 730-734. 
Pijnenburg MW, Bakker EM, Hop WC, De Jongste JC. Titrating steroids on exhaled nitric 
oxide in children with asthma: a randomised controlled trial. Am J Respir Crit Care Med 
2005;172:831-6.
7575
Pijnenburg MW, Bakker EM, Lever S, Hop WC, De Jongste JC. High fractional 
concentration of nitric oxide in exhaled air despite steroid treatment in asthmatic children. 
Clin Exp Allergy 2005; 35:920-5. 
Porsbjerg C, Rasmussen L, Thomsen SF, Brannan JD, Anderson SD, Backer V. 
Response to mannitol in asymptomatic subjects with airway hyper-responsiveness to 
methacholine. Clin Exp Allergy 2007;37(1):22-28. 
Porsbjerg C, Brannan JD, Anderson SD, Backer V. Relationship between airway 
responsiveness to mannitol and to methacholine and markers of airway inflammation, 
peak flow variability and quality of life in asthma patients. Clin Exp Allergy 2008;38:43-50. 
Postma DS, Bleecker ER, Amelung PJ, Holroyd KJ, Xu J, Panhuysen CI, Meyers DA, 
Levitt RC. Genetic susceptibility to asthma--bronchial hyperresponsiveness coinherited 
with a major gene for atopy. N Engl J Med 1995;333:894-900. 
Poston RN, Chanez P, Lacoste JY, Lichfield T, Lee TH, Bousquet J. Immunohistochemical 
characterization of the cellular infiltration in asthmatic bronchi. Am Rev Respir Dis 1992; 
145:918-921.
Prieto L, Gutierrez V, Uixera S. Exhaled nitric oxide and bronchial responsiveness to 
adenosine 5'-monophosphate in subjects with allergic rhinitis.  Chest 2002; 121:1853-9. 
Prieto L, Seijas T, Gutierrez V, Uixera S, Bruno L, López R. Exhaled nitric oxide levels and 
airway responsiveness to adenosine 5'-monophosphate in subjects with nasal polyposis. 
Int Arch Allergy Immunol 2004; 134:303-9.
Redington AE, Meng QH, Springall DR, Evans TJ, Creminon C, Maclouf J, Holgate ST, 
Howarth PH, Polak JM.  Increased expression of inducible nitric oxide synthase and cyclo-
oxygenase-2 in the airway epithelium of asthmatic subjects and regulation by 
corticosteroid treatment. Thorax. 2001;56:351-7. 
Reid DW, Johns DP, Feltis B, Ward C, Walters EH. Exhaled nitric oxide continues to 
reflect airway hyperresponsiveness and disease activity in inhaled corticosteroid-treated 
adult asthmatic patients. Respirology 2003; 8:479-86. 
Remes ST, Korppi M, Remes K. Outcome of children with respiratory symptoms without 
objective evidence of asthma: a two-year, prospective, follow-up study. Acta Paediatr 
1998; 87:165-168. 
Robbins RA, Barnes PJ, Springall DR, Warren JB, Kwon OJ, Buttery LD, Wilson AJ, Geller 
DA, Polak JM. Expression of inducible nitric oxide in human lung epithelial cells. Biochem 
Biophys Res Commun 1994;203: 209-218. 
Robbins RA, Floreani AA, Von Essen SG, Sisson JH, Hill GE, Rubinstein I, Townley R. 
Measurement of exhaled nitric oxide by three different techniques. Am J Respir Crit Care 
Med 1996; 153: 1631-1635.
7676
Rodger IW.  Role of leukotrienes and leukotriene receptor antagonist in asthma: new 
advances. J Investig Allergol Clin Immunol. 1997;7:279. 
Rogers DF, O´Connor BJ. Airway hyperresponsiveness: relation to asthma and 
inflammation? Thorax 1993; 48: 1095-1096. 
Rouhos A, Kainu A, Karjalainen J, Lindqvist A, Piirilä P, Sarna S, Haahtela T, Sovijarvi 
ARA. Atopic sensitisation to common allergens without symptoms or signs of airway 
disorders does not increase exhaled nitric oxide. The Clinical Respiratory Journal 2008; 2: 
141–148.
Rundell KW, Wilber RL, Szmedra L, Jenkinson DM, Mayers LB, Im J. Exercise-induced 
asthma screening of elite athletes: field versus laboratory exercise challenge. Med Sci 
Sports Exerc 2000; 32: 309-316. 
Rytilä P, Metso T, Heikkinen K, Saarelainen P, Helenius IJ, Haahtela T. Airway 
inflammation in patients with symptoms suggesting asthma but with normal lung function. 
Eur Respir J 2000;16:824-830. 
Rytila P. Induced sputum for assessment of airway inflammation in patients with COPD, 
asthma and asthma-like symptoms. Dissertation, Helsinki University, 2002, Finland. 
http://ethesis.helsinki.fi/julkaisut/laa/kliin/vk/rytila/induceds.pdf 
Saleh D, Ernst P, Lim S, Barnes PJ, Giaid A. Increased formation of the potent oxidant 
peroxynitrite in the airways of asthmatic patients is associated with induction of nitric oxide 
synthase: effect of inhaled glucocorticoid. FASEB J. 1998;12:929-37. 
Salome CM Roberts AM Brown NJ, Dermand J, Marks GB, Woolcock AJ. Exhaled nitric 
oxide measurements in a population sample of young adults. Am J Respir Crit Care Med 
1999 ;159:911-6. 
Sandrini A, Ferreira IM, Gutierrez C, Jardim JR, Zamel N, Chapman KR. Effect of 
montelukast on exhaled nitric oxide and nonvolatile markers of inflammation in mild 
asthma. Chest. 2003;124:1334-40. 
Schwartz J, Schindler C, Zemp E, Perruchoud AP, Zellweger JP, Wutrich B, Leuenberger 
P, Ackermann-Liebrich U. Predictors of methacholine responsiveness in a general 
population. Chest 2002;122:812-820. 
Scollo M, Zanconato S, Ongaro R, Zaramella C, Zacchello F, Baraldi E. Exhaled nitric 
oxide and exercise-induced bronchoconstriction in asthmatic children.  Am J Respir Crit 
Care Med 2000; 161:1047-50. 
Sherrington CA, Mallol J. Early effects of inhaled steroids on airway hyperreactivity and 
pulmonary function in asthma. Pediatr Pulmonol 1999;27:376-82 
Silkoff PE, McClean PA, Slutsky AS, Caramori M, Chapman KR, Gutierrez C, Zamel N. 
Exhaled nitric oxide and bronchial reactivity during and after inhaled beclomethasone in 
mild asthma. J Asthma 1998; 35: 473-479.
7777
Silkoff PE, Mcclean PA, Slutsky AS, Furlott HG, Hoffstein E, Wakita S, Chapman KR, 
Szalai JP, Zamel N. Marked flow-dependence of exhaled nitric oxide using a new 
technique to exclude nasal nitric oxide. Am J Respir Crit Care Med 1997;155:260-267.
Silkoff PE, Romero FA, Gupta N, Townley RG, Milgrom H  Exhaled nitric oxide in children 
with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody. 
Pediatrics 2004; 113:308-12.
Silkoff PE, Wakita S, Chatkin J, Ansarin K, Gutierrez C, Caramori M, McClean P, Slutsky 
AS, Zamel N, Chapman KR. Exhaled nitric oxide after beta2-agonist inhalation and 
spirometry in asthma.  Am J Respir Crit Care Med Mar 1999; 159:940-4. 
Silvestri M, Spallarossa D, Yourukova VF, Battistini E, Fregonese B, Rossi GA. Orally 
exhaled nitric oxide levels are related to the degree of blood eosinophilia in atopic children 
with mild-intermitten asthma. Eur Respir J 1999; 13: 321-326. 
Silvestri M, Sabatini F, Sale R, Defilippi AC, Fregonese L, Battistini E, Biraghi MG, Rossi 
GA. Correlations between exhaled nitric oxide levels, blood eosinophilia, and airway 
obstruction reversibility in childhood asthma are detectable only in atopic individuals. 
Pediatr Pulmonol. 2003;35:358-363 
Simpson A, Custovic A, Pipis S, Adisesh A, Faragher B, Woodcock A. Exhaled nitric oxide, 
sensitisation, and exposure to allergens in patients with asthma who are not taking inhaled 
steroids. Am J Respir Crit Care Med 1999; 160: 45-49.
Smith AD, Cowan JO, Filsell S, McLachlan C, Monti-Sheehan G, Jackson P, Taylor DR. 
Diagnosing asthma: comparisons between exhaled nitric oxide measurements and 
conventional tests.  Am J Respir Crit Care Med 2004; 169:473-8. 
Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use of exhaled nitric oxide 
measurements to guide treatment in chronic asthma. N Engl J Med 2005; 352 :2163-73. 
Sont JK, Willems LN, Bel EH, Van Krieken JH, Vandenbroucke JP, Sterk PJ. Clinical 
control and histopathologic outcome of asthma when using airway hyperresponsiveness 
as an additional guide to long-term treatment. AMPUL Study Group. Am J Respir Crit Care 
Med 1999;159:1043–1051. 
Sovijärvi ARA, Malmberg LM, Reinikainen K, Rytilä P, Poppius H. A rapid dosimetric 
method with controlled tidal breathing for histamine challenge. Chest 1993; 104: 164-170. 
Steerenberg PA, Janssen NA, de Meer G, Fischer PH, Nierkens S, van Loveren H, 
Opperhuizen A, Brunekreef B, van Amsterdam JG. Relationship between exhaled NO, 
respiratory symptoms, lung function, bronchial hyperresponsiveness, and blood 
eosinophilia in school children. Thorax 2003; 58:242-5  
Steerenberg PA, Snelder JB, Fischer PH, Vos JG, van Loveren H, van Amsterdam JGC. 
Increased exhaled nitric oxide on days with high outdoor air pollution is of endogenous 
origin. Eur Respir J 1999; 13: 334-337.
7878
Sterk PJ and Bel EH. Bronchial hyperresponsiveness: the need for a distinction between 
hypersensitivity and excessive airway narrowing. Eur Respir J 1989; 2: 267-274. 
Stirling RG, Kharitonov SA, Campbell D, Robinson DS, Durham SR, Chung KF, Barnes 
PJ. Increase in exhaled nitric oxide levels in patients with difficult asthma and correlation 
with symptoms and disease severity despite treatment with oral and inhaled 
corticosteroids. Thorax 1998; 53:1030-4. 
Strauch E, Moske O, Thoma S, Storm Van's Gravesande K, Ihorst G, Brandis M, Kuehr J.
A randomised controlled trial on the effect of montelukast on sputum eosinophil cationic 
protein in children with corticosteroid-dependent asthma. Pediatr Res.2003;54:198-203. 
Stuehr DJ, Marlette MA. Mammalian nitrate biosynthesis: mouse macrophages produce 
nitrite and nitrate in response to Escherichia Coli lipopolysaccharide. Proc Natl Acad Sci 
USA 1985;82: 7738-7742. 
Sur S, Crotty TB, Kephart GM, Hyma BA, Colby TV, Reed CE, Hunt LW, Gleich GJ. 
Sudden-onset fatal asthma. A distinct entity with few eosinophils and relatively more 
neutrophils in the airway submucosa?  Am Rev Respir Dis 1993; 148:713-9. 
Taylor ES, Smith AD, Cowan JO, Herbison P, Taylor DR. Effect of Caffeine Ingestion on 
Exhaled Nitric Oxide Measurements in Patients with Asthma. Am J Respir Crit Care Med 
2004;169:1019 -1021. 
ten Hacken NH, van der Vaart H, van der Mark TW, Koëter GH, Postma DS. Exhaled nitric 
oxide is higher both at day and night in subjects with nocturnal asthma. Am J Respir Crit 
Care Med 1998;158:902-907.
Terada A, Fujisawa T, Togashi K, Miyazaki T, Katsumata H, Atsuta J, Iguchi K, Kamiya H, 
Togari H. Exhaled nitric oxide decreases during exercise-induced bronchoconstriction in 
children with asthma. Am J Respir Crit Care Med 2001; 164: 1879-1884. 
Tsoukias NM, George SC. A two-compartment model of pulmonary nitric oxide exchange 
dynamics. J Appl Physiol 1998;85(2):653-66. 
Tsurikisawa N, Tsuburai T, Oshikata C, Ono E, Saito H, Mitomi H, Akiyama K. Prognosis 
of adult asthma after normalization of bronchial hyperresponsiveness by inhaled 
corticosteroid therapy. J Asthma 2008;45:445-451. 
van den Toorn LM, Overbeek SE, de Jongste JC, Leman K, Hoogsteden HC, Prins JB. 
Airway inflammation is present during clinical remission of atopic asthma. Am J Respir Crit 
Care Med 2001; 164: 2107-2113. 
van den Toorn LM, Prins JB, Overbeek SE, Hoogsteden HC, de Jongste JC. Adolescents 
in clinical remission of atopic asthma have elevated exhaled nitric oxide levels and 
bronchial hyperresponsiveness. Am J Respir Crit Care Med 2000; 162: 953-957. 
van Grunsven PM, van Schayck CP, Molema J et al. Effect of inhaled corticosteroids on 
bronchial responsiveness in patients with “corticosteroid naive” mild asthma: a meta-
analysis. Thorax 1999;54:316–22. 
7979
van Rensen EL, Straathof KC, Veselic-Charvat MA, Zwinderman AH, Bel EH, Sterk PJ. 
Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and 
exhaled nitric oxide levels in patients with asthma. Thorax 1999; 54: 403-408. 
van Schoor J, Joos GF, Pauwels RA. Indirect bronchial hyperresponsiveness in asthma: 
mechanisms, pharmacology and implications for clinical research. Eur Respir J 
2000;16:514-33.
Vathenen AS, Knox AJ, Wisniewski A, Tattersfield AE. Time course of change in bronchial 
reactivity with an inhaled corticosteroid in asthma. Am Rev Respir Dis 1991;143:1317–21. 
Vignola AM, Bousquet J, Chanez P, Gagliardo R, Merendino AM, Chiappara G, Bosignore 
G. Assessment of airway inflammation in asthma. Am J Respir Crit Care Med 
1998;157:S814-S187. 
Viljanen AA, Halttunen PK, Kraus K-E, Viljanen BC. Spirometric studies in non-smoking, 
healthy adults. Scand J Clin Lab Invest 1982;42 (Suppl. 159):5-20. 
Virant FS. Exercise-induced bronchospasm: epidemiology, pathophysiology, and therapy. 
Med Sci Sports Exerc 1992;24:851-5. 
Ward C, Pais M, Bish R, Reid D, Feltis B, Johns D, Walters EH. Airway inflammation, 
basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax. 
2002;57:309-16.
Warke TJ, Fitch PS, Brown V, Taylor R, Lyons JD, Ennis M, Shields MD. Exhaled nitric 
oxide correlates with airway eosinophils in childhood asthma. Thorax. 2002;57:383-7. 
Wassermann SI. Mast cells and airway inflammation in asthma. Am J Respir Crit Care 
Med 1994;150:S39-S41. 
Wenzel SE Szefler SJ Leung DY, Sloan SI, Rex MD, Martin RJ. Bronchoscopic evaluation 
of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am J 
Respir Crit Care Med 1997; 156:737-43. 
Wilson AM Dempsey OJ Sims EJ Lipworth BJ. Evaluation of salmeterol or montelukast as 
second-line therapy for asthma not controlled with inhaled corticosteroids. Chest 2001; 
119:1021-6
Wink DA, Hanbauer I, Grisham MB, Laval F, Nims RW, Laval J, Cook J, Pacelli R, 
Liebmann J, Krishna M, Ford PC, Mitchell JB. Chemical biology of nitric oxide: regulation 
and protective and toxic mechanisms. Curr Top Cell Regul 1996;34:159-187. 
Yates DH, Kharitonov SA, Robbins RA, Thomas PS, Barnes PJ. The effect of alcohol 
ingestion on exhaled nitric oxide. Eur Respir J 1996; 9: 1130-1133. 
Yates DH, Kharitonov SA, Barnes PJ. Effect of short- and long-acting inhaled beta2-
agonists on exhaled nitric oxide in asthmatic patients. Eur Respir J 1997; 10:1483-8. 
8080
81
Yoshikawa T, Shoji S, Fujii T: Severity of exercise-induced bronchoconstriction is related 
to airway eosinophilic inflammation in patients with asthma. Eur Respir J 1998; 12: 879-
884.
Zetterquist W, Pedroletti C, Lundberg JON, Alving K. Salivary contribution to exhaled nitric 
oxide. Eur Respir J 1999;13:327-333.
81
